Review Recurring Topics

The Function of Sleep

  • Received: 30 March 2015 Accepted: 10 June 2015 Published: 18 June 2015
  • The importance of sleep can be ascertained by noting the effects of its loss, which tends to be chronic and partial, on cognition, mood, alertness, and overall health. Many theories have been put forth to explain the function of sleep in humans, including proposals based on energy conservation, ecological adaptations, neurocognitive function, neural plasticity, nervous system and physical health, and performance. Most account for only a portion of sleep behavior and few are based on strong experimental support. In this review, we present theories proposing why sleep is necessary and supporting data demonstrating the effects of inadequate sleep, with the intention of gleaning further information as to its necessity, which remains one of the most perplexing mysteries in biology.

    Citation: Daniel A. Barone, Ana C. Krieger. The Function of Sleep[J]. AIMS Neuroscience, 2015, 2(2): 71-90. doi: 10.3934/Neuroscience.2015.2.71

    Related Papers:

    [1] Urszula Foryś, Jan Poleszczuk . A delay-differential equation model of HIV related cancer--immune system dynamics. Mathematical Biosciences and Engineering, 2011, 8(2): 627-641. doi: 10.3934/mbe.2011.8.627
    [2] Katrine O. Bangsgaard, Morten Andersen, Vibe Skov, Lasse Kjær, Hans C. Hasselbalch, Johnny T. Ottesen . Dynamics of competing heterogeneous clones in blood cancers explains multiple observations - a mathematical modeling approach. Mathematical Biosciences and Engineering, 2020, 17(6): 7645-7670. doi: 10.3934/mbe.2020389
    [3] Thanh Nam Nguyen, Jean Clairambault, Thierry Jaffredo, Benoît Perthame, Delphine Salort . Adaptive dynamics of hematopoietic stem cells and their supporting stroma: a model and mathematical analysis. Mathematical Biosciences and Engineering, 2019, 16(5): 4818-4845. doi: 10.3934/mbe.2019243
    [4] Jie Lou, Tommaso Ruggeri, Claudio Tebaldi . Modeling Cancer in HIV-1 Infected Individuals: Equilibria, Cycles and Chaotic Behavior. Mathematical Biosciences and Engineering, 2006, 3(2): 313-324. doi: 10.3934/mbe.2006.3.313
    [5] J. Ignacio Tello . On a mathematical model of tumor growth based on cancer stem cells. Mathematical Biosciences and Engineering, 2013, 10(1): 263-278. doi: 10.3934/mbe.2013.10.263
    [6] Abeer S. Alnahdi, Muhammad Idrees . Nonlinear dynamics of estrogen receptor-positive breast cancer integrating experimental data: A novel spatial modeling approach. Mathematical Biosciences and Engineering, 2023, 20(12): 21163-21185. doi: 10.3934/mbe.2023936
    [7] Eminugroho Ratna Sari, Fajar Adi-Kusumo, Lina Aryati . Mathematical analysis of a SIPC age-structured model of cervical cancer. Mathematical Biosciences and Engineering, 2022, 19(6): 6013-6039. doi: 10.3934/mbe.2022281
    [8] Haifeng Zhang, Jinzhi Lei . Optimal treatment strategy of cancers with intratumor heterogeneity. Mathematical Biosciences and Engineering, 2022, 19(12): 13337-13373. doi: 10.3934/mbe.2022625
    [9] Qiaojun Situ, Jinzhi Lei . A mathematical model of stem cell regeneration with epigenetic state transitions. Mathematical Biosciences and Engineering, 2017, 14(5&6): 1379-1397. doi: 10.3934/mbe.2017071
    [10] Hongli Yang, Jinzhi Lei . A mathematical model of chromosome recombination-induced drug resistance in cancer therapy. Mathematical Biosciences and Engineering, 2019, 16(6): 7098-7111. doi: 10.3934/mbe.2019356
  • The importance of sleep can be ascertained by noting the effects of its loss, which tends to be chronic and partial, on cognition, mood, alertness, and overall health. Many theories have been put forth to explain the function of sleep in humans, including proposals based on energy conservation, ecological adaptations, neurocognitive function, neural plasticity, nervous system and physical health, and performance. Most account for only a portion of sleep behavior and few are based on strong experimental support. In this review, we present theories proposing why sleep is necessary and supporting data demonstrating the effects of inadequate sleep, with the intention of gleaning further information as to its necessity, which remains one of the most perplexing mysteries in biology.


    Myeloproliferative Neoplasms (MPNs) is a group of hematopoietic stem cell disorders, including essential thrombocytosis (ET), polycythemia vera (PV) and primary myelofibrosis (PMF) [1,2]. The pathogenesis of these neoplasms is yet to be fully discovered. For patients with MPNs, the mutation $ JAK2 $V617F is found present in the most cases of ET (50%) and in 95% of the cases with PV and PMF ultimately leading to acute myeloid leukemia (AML) [3,4]. This suggests a biological continuum where the diseases evolve from early cancers (ET and PV) into the advanced myelofibrosis stage, with an increasing load of $ JAK2 $V617F mutations from a low burden at ET and PV to a high load [2,5]. MPNs imply an increased risk for the development of other cancers [1,4].

    Recent research supports that MPNs can be regarded as chronic inflammatory diseases and MPNs has been described as a "human inflammation model", which leads to premature atherosclerosis, clonal evolution and an increased risk of second cancers. [2,3,6]. This is based on evidence from clinical observations, experiments and molecular studies [3].

    Several insightful theoretical studies have been published on control dynamics of biological networks. Mathematical models have been proposed [7,8,9] describing the control networks for regulation of stem cell lineage.Mathematical modelling of cancer is useful for understanding of cancer initiation, progression [10,11], to confirm or dismiss biological/medical hypotheses, and to study effects of single or multi modality treatments in silico. The mathematical model presented in [12] shows that successful therapy may eliminate tumour stem cells. A five-dimensional model given in [13] includes active and quiescent stem cells, progenitor cells, mature cells and one immune compartment describing chronic myelogenous leukemia.In [14] a mathematical model of cancer stem cell dynamics is proposed and the different scenarios of cancer initiation and possible treatments strategies have been discussed. The mathematical model given in [15] is useful for investigating the impact of cytokine-dependence of acute myeloid leukemic cells. In addition, the model allows distinguishing between cytokine-dependent and cytokine-independent acute myeloid leukemia (AML) and both scenarios are supported by patient data.

    However, only a few mathematical models of MPNs exist. Some work includes investigation of the origin of myeloid malignancies with MPNs as a particular example [16]. In [17], a two dimensional model of MPNs is investigated without including the immune response dynamically. The Cancitis model including chronic inflammation as the trigger and driver of MPNs was proposed in [5]. In [5], T-cells are not explicitly considered whereas, in [18], the effect of these cells has been included specifically. The analysis of a two dimensional mathematical model [18] is used to discuss in silico effect of existing and novel treatments. The model presented here is identical to the model presented in [5] except for the simpler functional form of the stem cells niche interaction used here and in [18].

    In the present paper we conduct a thorough mathematical investigation of the Cancitis model and explore the intricate coupling between inflammation and MPNs. We address the following questions which have not been systematically investigated previously: Which steady states of the system are feasible and which trajectories are attracted to the steady states? How do the number and stability of the steady states change when varying the parameters, in particular, the exogenous inflammatory stimuli, self-renewal and death rates of stem cells, and inhibitory strength of the stem cell niche interaction? Which set of clustered parameters control the dynamics of the system? Does the analysis suggest correlated parameters? The bio-medical applications of the model analysis are discussed, e.g. how the inflammation influences the transition between healthy and diseased states. In addition, the analysis predicts effects of ongoing and potential combination therapies.

    The Cancitis model stated in [5] is illustrated in Figure 1, with the system of differential equations shown in system (2.1). In this section the details of the model and the reasoning behind it is presented.

    Figure 1.  The boxes illustrate the compartments of the Cancitis model. The arrows represent the rates of the flows between and out of these compartments. Red stipulated arrows represent the effect of inflammation which is stimulated by exogenous inflammatory stimuli, $ I $. Green stipulated lines represent the bone marrow niches interaction with a 'crowding' competition between HSC and MSC. Stem cells (HSC and MSC) may self-renew, die or differentiate, while mature cells die after a while (MMC, HMC). Dead cells ($ a $) are engulfed by the immune cells ($ s $), that stimulate production of stem cells, increase risk of mutation and increase the removal of dead cells (For more details, see main text).

    The model describes the proliferation of hematopoietic stem cells (HSC) into hematopoietic mature cells (HMC) and likewise malignant stem cells (MSC) into malignant mature cells (MMC). Additionally, the model considers the number of dead cells and the level of inflammation. The debris from the dead cells stimulates the immune response, which in turn affects the self-renewal rate of both HSCs and MSCs.

    The model consists of six ordinary differential equations one for each compartment; the number of HSC ($ x_0 $), the number of HMC ($ x_1 $), the number of MSC ($ y_0 $), the number of MMC ($ y_1 $), the number of dead cells ($ a $), and the level of inflammation ($ s $).

    The equations are of the general form,

    $ \left\{ Change in amount of acompartment per time
    \right\} = \left\{ rate of production timesthe producing source 
    \right\}-\left\{ rate of elimination times theamount in the compartment
    \right\}. $

    and read specifically,

    $ ˙x0=rx(ϕxsαx)x0rmsx0,
    $
    (2.1a)
    $ ˙x1=axAxx0dx1x1,
    $
    (2.1b)
    $ ˙y0=ry(ϕysαy)y0+rmsx0,
    $
    (2.1c)
    $ ˙y1=ayAyy0dy1y1,
    $
    (2.1d)
    $ ˙a=dx0x0+dy0y0+dx1x1+dy1y1eaas,
    $
    (2.1e)
    $ ˙s=rsaess+I,
    $
    (2.1f)

    with

    $ αx=dx0+axrxandαy=dy0+ayry.
    $
    (2.2)

    The expressions for the inhibitory niche feedback are chosen as Michaelis-Menten-like functions in contrast to [5],

    $ ϕxϕx(x0,y0)=11+cxxx0+cxyy0,
    $
    (2.3a)
    $ ϕyϕy(x0,y0)=11+cyxx0+cyyy0.
    $
    (2.3b)

    A stem cell can proliferate in three ways; symmetric self-renewal (resulting in two new stem cells), asymmetric self-renewal (resulting in one stem cell and one progenitor cell) and symmetric differentiation (resulting in two progenitor cells). The rate of self-renewal is denoted as $ r_x $ and $ r_y $ for HSC and MSC respectively. The self-renewal of stem cells is known to be inhibited by self-regulating niche feedback [19], resulting in decreased self-renewal when the level of stem cells in the bone marrow is high. Adopting the approach taken in [12], [20] and [21], this is implemented by Michaelis-Menten-like functions $ \phi_x(x_0, y_0) $ and $ \phi_y(x_0, y_0) $, shown in Eq (2.3b). Allowing the feedback to be different for HSC and MSC, the constants $ c_{xx} $ and $ c_{xy} $ capture the effects of HSC and MSC on the self-renewal of HSC, while $ c_{yx} $ and $ c_{yy} $ capture the corresponding effects on the self-renewal of MSC. Additionally, the inflammatory level also affects the self-renewal [22,23]. This leads a to self-renewal term per cell of $ r_x \phi_x s $ and $ r_y \phi_y s $ for HSC and MSC respectively. The parameter $ c_{ij} $ describes the inhibitory strength of the signalling bone marrow niche feedback from cell type $ j $ onto cell type $ i $. It is generally assumed that $ c_{yy}\leq c_{yx} \leq c_{xy} \leq c_{xx} $, since malignant cells are less sensitive to inhibitive niche feedback than hematopoietic cells [22,24].

    In [25], a multi compartmental model is proposed relying on a single external feedback mechanism. It is shown that the equilibrium level of mature cells depends only on the self-renewal parameters for the HSC and it is independent of the other compartments. Therefore, the progenitor cells are considered as intermediate steps between stem cells and mature cells, and are implicitly accounted for by multiplication factors $ A_x $ and $ A_y $ for HSC and MSC respectively. The rate at which the HSC reduces in transforming to HMC is denoted by $ a_x $ while the similar rate for MSC transforming to MMC is denoted by $ a_y $. As such, the HMC and MMC accordingly increase with rates $ a_x A_x $ and $ a_y A_y $ respectively. To account for the cell apoptosis, the four types of cells are removed with rates $ d_{x_0} $, $ d_{x_1} $, $ d_{y_0} $ and $ d_{y_1} $, for the corresponding cell types.

    Genetic mutations are by nature to be described as Poisson processes [26,27,28,29]. However, not all mutations are malignant; only mutation which happens on a particular location of the DNA, i.e. at specific amino acids causes a specific mutation, e.g. the JAK2V617F mutation. The probability for hitting a specific location is about 1/30000. In [30] the average mutation probability is estimated to 0.0035 per year, which corresponds to a specific mutation probability of $ 0.0035/30000 = 1.2 10^{-7} $ per year. Thus, the probability for one specific malignant mutation is about $ 10^{-7} $ per cell per year. Moreover, the mutation is affected by the inflammation, $ s $ [31,32], which is explicitly stated, and resulting in the effective mutation rate $ r_m s $. Assuming three sequential mutations are needed to generate a specific malignant stem cell the resulting probability becomes much higher ($ 10^{-25} $ per year per cell if the mutations are assumed independent). This could be implemented in the otherwise deterministic model but it would increase the computational cost, since it depends on both the probability of a single cell mutation and the number of potential mutating cells at a given time, which itself is determined by the preceding mutational history. To avoid such complications we initialize by having a single MSC and none MMC, and put the mutation rate to zero. This is justified by the fact that the probability of a single cell mutating is small compared to the self-renewal of the MSCs. Thus, the first mutation drives the development leaving a later identical mutation insignificant to the dynamics, which is confirmed by numerical simulations.

    The number of dead cells has an up-regulatory effect on the immune response denoted $ r_s $. External environmental factors also influence the inflammatory level. This is captured in the model by the term $ I $. Throughout we take $ I > 0 $, as a perfect sterile environment is an utopic idealization. This term may vary over time due to environmental changes, but in our mathematical analysis we will consider $ I $ as piecewise constant. The inflammation, $ s $, is down-regulated naturally by the eliminating rate $ e_s $.

    Additionally, the change in the amount of dead cells per time is given by the death rate times the number of cells minus the clearance by the immune system. As given in [33] clearance is described by a second order equation $ -e_a a s $ since the engulfed immune cells have to meet the dead cells debris to mediate endocytosis. Thus, clearance is bilinear in both $ a $ and $ s $ representing the activity of the immune system, eliminating the dead cells with an elimination rate $ e_a $.

    Initial conditions for the Cancitis model in equations are needed for the given system of differential equations (2.1–2.3b). Here, we mainly focus on the model after the first mutation, i.e. with $ y_0(0) = 1 $, $ y_1(0) = 0 $, $ r_m = 0 $, and the remaining variables as those in the healthy steady state (see below). All other parameter values are assumed to be positive.

    The stable steady states are attractors in the six dimensional phase space. This motivates systematic study of the existence and location of steady states and how this is affected by perturbing parameter values.

    Motivated by the biology where the number of cells and concentrations are required to be non-negative numbers, we will use the terminology that a steady state is admissible if and only if all the components are non-negative, i.e. if and only if a steady state is in the non-negative octahedron.

    Consider the system of Eqs (2.1–2.3b). For steady state solutions, $ \dot{x}_0 = \dot{x}_1 = \dot{y}_0 = \dot{y}_1 = \dot{a} = \dot{s} = 0 $,

    $ (ˉsαx(1+cxxˉx0+cxyˉy0))ˉx0=0,
    $
    (2.4a)
    $ (ˉsαy(1+cyxˉx0+cyyˉy0))ˉy0=0,
    $
    (2.4b)
    $ ˉx1=axAxˉx0dx1,
    $
    (2.4c)
    $ ˉy1=ayAyˉy0dy1,
    $
    (2.4d)
    $ dx0ˉx1+dx1ˉx1+dy0ˉy0+dy1ˉy1eaˉaˉs=0,
    $
    (2.4e)
    $ ˉa=esrs(ˉsIes).
    $
    (2.4f)

    The values of $ x_0 $, $ x_1 $, $ y_0 $, $ y_1 $, $ a $ and $ s $ at steady state are denoted as $ \bar{x}_0 $, $ \bar{x}_1 $, $ \bar{y}_0 $, $ \bar{y}_1 $, $ \bar{a} $ and $ \bar{s} $ respectively. The admissible steady states can be classified as,

    ● a trivial steady state if and only if $ \bar{x}_0 = \bar{y}_0 = 0 $,

    ● a (purely) hematopoietic steady state if and only if $ \bar{y}_0 = 0 $ and $ \bar{x}_0 > 0 $,

    ● a (purely) malignant steady state if and only if $ \bar{x}_0 = 0 $ and $ \bar{y}_0 > 0 $, or

    ● a co-existing steady state if and only if $ \bar{x}_0 > 0 $ and $ \bar{y}_0 > 0 $.

    The admissibility of steady states necessitates certain inequalities to be fulfilled, which leads to restriction on the parameters, e.g. from Eq (2.4f), non-negativity of $ \bar{a} $ requires $ \bar{s} \geq \frac{I}{e_s} $. $ I $ is assumed to be positive thus $ \frac{I}{e_s} > 0 $. Hence

    $ ˉsIes>0,
    $
    (2.5)

    for any admissible steady state. Note that, $ \bar{x}_1 $ and $ \bar{y}_1 $ are non-negative if and only if $ \bar{x}_0 $ and $ \bar{y}_0 $ are non-negative, respectively. Substituting expressions of $ \bar{x}_1 $ and $ \bar{y}_1 $ in Eq (2.4e) gives,

    $ eaˉaˉs=βxˉx0+βyˉy0,
    $
    (2.6)

    where $ \beta_x = a_x A_x+d_{x0} $ and $ \beta_y = a_y A_y+ d_{y0} $. Thus, Eqs (2.4e–2.4f) and (2.6) result in a second order equation in $ \bar{s} $ having the general solution,

    $ ˉs±=I2es(1±1+ζ(βxˉx0+βyˉy0)),
    $
    (2.7)

    where $ \zeta = \frac{4 r_s e_s}{e_a I^2} > 0 $. $ \bar{s}_- $ is negative for positive $ \bar{x}_0 $ or $ \bar{y}_0 $. In case, $ (\bar{x}_0, \bar{y}_0) = (0, 0) $, Eq (2.7) leads to $ \bar{s}_{-} = 0 $ contradicting $ \bar{s} > 0 $. Thus, $ s = \bar{s}_- $ is not biologically realizable and we therefore put $ \bar{s} = \bar{s}_+ $ in the further analysis. Note that, for non-trivial steady states, $ \bar{s} > \frac{I}{e_s} $. In addition, non-negativity of $ \bar{x}_0 $ and $ \bar{y}_0 $ implies non-negativity of $ \bar{x}_1 $, $ \bar{y}_1 $, $ \bar{s} $ and $ \bar{a} $.

    Hence, the existence of admissible steady states $ \bar{x}_0 $, $ \bar{y}_0 $, $ \bar{x}_1 $, $ \bar{y}_1 $, $ \bar{s} $ and $ \bar{a} $ follows from Eqs (2.4a), (2.4b) and (2.7).

    Below we make a complete analysis of the existence of various steady states depending on how $ I $ relates to the remaining parameters. This choice is due to the fact that the external inflammatory stimuli $ I $ is of great interest in health care and to elucidate consequences of using inflammation inhibitors as part of treatment.

    Proposition 1. A trivial steady state $ E_{0} $ always exists,

    $ E0=(0,0,0,0,0,Ies).
    $
    (2.8)

    Proof. Follow directly from Eqs (2.4e) and (2.5).

    Hematopoietic steady states may exist depending on the rest of the parameter values. As above we chose the inflammatory stimuli $ I $ as the leading parameter and make a complete analysis of possible hematopoietic steady states. The analysis of the existence of the hematopoietic steady states depends crucially on the following lumped parameters,

    $ IH=2esrsβxeacxxrsβxeacxxαx,
    $
    (2.9)
    $ ζH1=2esαxrsβxeacxxαx,
    $
    (2.10)
    $ ζH2=esαx,
    $
    (2.11)
    $ ζH3=rsβxeseacxx,
    $
    (2.12)

    the last two always being positive.

    Proposition 2. Two hematopoietic steady states $ E_{H\pm} $ may exist in the following cases,

    If $ \alpha_x^2 \leq \frac{\zeta_{H3}}{4} $ then $ E_{H+} $ exists if and only if $ I > 0 $.

    If $ \frac{\zeta_{H3}}{4} < \alpha_x^2 \leq \zeta_{H3} $ then $ E_{H+} $ exists if and only if $ I \geq I_{H} $.

    If $ \zeta_{H3} < \alpha_x^2 $ then $ E_{H+} $ exists if and only if $ I > \zeta_{H2} $.

    If $ \alpha_x^2 \leq \frac{\zeta_{H3}}{4} $ then $ E_{H-} $ exists if and only if $ I \leq \zeta_{H2} $.

    If $ \frac{\zeta_{H3}}{4} < \alpha_x^2 \leq \zeta_{H3} $ then $ E_{H-} $ exists if and only if $ I_{H} \leq I \leq \zeta_{H2} $.

    If $ \zeta_{H3} < \alpha_x^2 $ then $ E_{H-} $ does not exist.

    In case of existence, $ E_{H+} = (\bar{x}_{0H+}, \bar{x}_{1H+}, 0, 0, \bar{a}_{H+}, \bar{s}_{H+}) $ is given by $ \bar{x}_{0H+} = \frac{1}{2 e_s c_{xx}\alpha_x} \left(I-\zeta_{H1} + \sqrt{(\zeta_{H1}-I)^2-4 e_s \alpha_x(\zeta_{H2}-I)}\right) $, $ \bar{s}_{H+} = \alpha_x (1+c_{xx} \bar{x}_{0H+}) $, $ \bar{a}_{H+} = \frac{\beta_x \bar{x}_{0H+}}{e_a \bar{s}_{H+}} $, and $ \bar{x}_{1H+} = \frac{a_x A_x \bar{x}_{0H+}}{d_{x1}} $ whereas $ E_{H-} = (\bar{x}_{0H-}, \bar{x}_{0H-}, 0, 0, \bar{a}_{H-}, \bar{s}_{H-}) $ is given by $ \bar{x}_{0H-} = \frac{1}{2 e_s c_{xx}\alpha_x} \left(I-\zeta_{H1} - \sqrt{(\zeta_{H1}-I)^2-4 e_s \alpha_x(\zeta_{H2}-I)}\right) $, $ \bar{s}_{H-} = \alpha_x (1+c_{xx} \bar{x}_{0H-}) $, $ \bar{a}_{H-} = \frac{\beta_x \bar{x}_{0H-}}{e_a \bar{s}_{H-}} $, and $ \bar{x}_{1H-} = \frac{a_x A_x \bar{x}_{0H-}}{d_{x1}} $.

    Proof. A hematopoietic steady state $ E_{H} $ follows from Eqs (2.4a) and (2.7) with $ y_0 = y_1 = 0 $ as possible positive solutions to

    $ ˉx20H+1escxxαx(ζH1I)ˉx0H+1esc2xxαx(ζH2I)=0.
    $
    (2.13)

    For the solutions to (2.13) to be real,

    $ (ζH1I)24ζH2(ζH2I).
    $
    (2.14)

    In case $ I\geq\zeta_{H2} $, (2.14) is always fulfilled. In case $ I < \zeta_{H2} $, (2.14) is equivalent to

    $ I2+2rsβxeacxxαxI+rsβxeacxxαx(rsβxeacxxαx4esαx)0.
    $
    (2.15)

    Solving for $ I $ we get,

    $ IIH=γx(α2xζH34),
    $
    (2.16)

    with

    $ γx=4esrsβxeacxxα2xrsβxeacxxαx+2esrsβxeacxx>0.
    $
    (2.17)

    From Eqs (2.14) and (2.16) it follows that the solutions to Eq (2.13) are real for $ I\geq\zeta_{H2} $ or $ I_H\leq I < \zeta_{H2} $ in case $ I_H < \zeta_{H2} $.

    Whenever the solutions to (2.13) are real, they are given by

    $ ˉx0H±:=12escxxαx(IζH1±(ζH1I)24esαx(ζH2I)),
    $
    (2.18)

    which depends on the sign of the following five quantities,

    $ ζH1=2esαx(α2xζH32),
    $
    (2.19)
    $ IH=γx(α2xζH34),
    $
    (2.20)
    $ Δ12=ζH1ζH2=esαx(α2xζH3),
    $
    (2.21)
    $ ΔH1=ζH1IH=esαx+ζH3(α2xζH3), and 
    $
    (2.22)
    $ ΔH2=IHζH2=esαx(αx+ζH3)2(α2xζH3)20,
    $
    (2.23)

    where the last one immediately implies that the criteria for real solutions of Eq (2.13) is $ I\geq I_H $. If the solutions, $ \bar{x}_{0H\pm} $, are positive and real, then the formulas for the remaining variables easily follow from Eqs (2.4a–2.4f).

    To continue we first consider $ \bar{x}_{0H+} $ and afterwards $ \bar{x}_{0H-} $.

    For $ \alpha_x^2 \leq \frac{\zeta_{H3}}{4} $, it follows from Eqs (2.19)–(2.22) that $ \zeta_{H1} < 0 $, $ \zeta_{H1} < \zeta_{H2} $, $ I_H\leq 0 $, and $ \zeta_{H1} < I_H $. Thus, $ \bar{x}_{0H+} > 0 $ if and only if $ I > 0 $.

    For $ \frac{\zeta_{H3}}{4} < \alpha_x^2 \leq \frac{\zeta_{H3}}{2} $, it follows from Eqs (2.19)–(2.22) that $ \zeta_{H1}\leq 0 $, $ \zeta_{H1} < \zeta_{H2} $, $ I_H > 0 $, and $ \zeta_{H1} < I_H $. Thus, $ \bar{x}_{0H+} > 0 $ if and only if $ I > I_H $.

    For $ \frac{\zeta_{H3}}{2} < \alpha_x^2 \leq \zeta_{H3} $, it follows from Eqs (2.19)–(2.22) that $ \zeta_{H1} > 0 $, $ \zeta_{H1}\leq \zeta_{H2} $, $ I_H > 0 $, $ \zeta_{H1} < I_H $, and $ I_H\leq\zeta_{H2} $. Thus, $ \bar{x}_{0H+} > 0 $ if and only if $ I > I_H $.

    For $ \zeta_{H3} < \alpha_x^2 $ are $ \zeta_{H1} > 0 $, it follows from Eqs (2.19)–(2.23) that $ \zeta_{H1} > \zeta_{H2} $, $ I_H > 0 $, $ \zeta_{H1} > I_H $, and $ I_H\leq\zeta_{H2} $. Thus, $ \bar{x}_{0H+} > 0 $ if and only if $ I > \zeta_{H2} $.

    Similar, $ \bar{x}_{0H-} $ is real if and only if $ I \geq I_H $ and $ \zeta_{H1} < I < \zeta_{H2} $.

    For $ \alpha_x^2 \leq \frac{\zeta_{H3}}{4} $, it follows from Eqs (2.19) and (2.20) that $ \zeta_{H1} < 0 < \zeta_{H2} $, and $ I_H\leq 0 $. Thus, $ \bar{x}_{0H-} > 0 $ if and only if $ I < \zeta_{H2} $.

    For $ \frac{\zeta_{H3}}{4} < \alpha_x^2 \leq \frac{\zeta_{H3}}{2} $, it follows from Eqs (2.19), (2.20) and (2.23) that $ \zeta_{H1}\leq 0 < \zeta_{H2} $, $ I_H > 0 $, and $ I_H < \zeta_{H2} $. Thus, $ \bar{x}_{0H-} > 0 $ if and only if $ I_H\leq I < \zeta_{H2} $.

    For $ \frac{\zeta_{H3}}{2} < \alpha_x^2 \leq \zeta_{H3} $, it follows from Eqs (2.19)- (2.21) and (2.23) that $ 0 < \zeta_{H1} < \zeta_{H2} $, $ I_H > 0 $, and $ I_H < \zeta_{H2} $. Thus, $ \bar{x}_{0H-} > 0 $ if and only if $ I_H\leq I < \zeta_{H2} $.

    For $ \zeta_{H3} < \alpha_x^2 $, it follows from Eqs (2.20) and (2.21) that $ \zeta_{H1} > \zeta_{H2} $ and $ I_H > 0 $. Thus, $ \bar{x}_{0H-} > 0 $ if and only if $ \zeta_{H1} < I < \zeta_{H2} $, which is a contradiction.

    The conditions for the existence of the hematopoietic steady states are summarized in Table 1.

    Table 1.  Summarizing necessary and sufficient criteria for admissibility of $ E_H $. The first column conditions how $ \alpha_x $ is related to $ \zeta_{H3} $, the middle column shows the existence conditions for $ E_{H+} $ and the last column shows the existence conditions for $ E_{H\pm} $ explicitly in terms of $ I $.
    For Only $ E_{H+} $ if Both $ E_{H+} $ and $ E_{H-} $ if
    $ \alpha_x^2 < \frac{\zeta_{H3}}{4} $ $ I > \zeta_{H2} $ $ I \leq \zeta_{H2} $
    $ \frac{\zeta_{H3}}{4} < \alpha_x^2 < \zeta_{H3} $ $ I > \zeta_{H2} $ $ I_{H} \leq I \leq \zeta_{H2} $
    $ \zeta_{H3} < \alpha_x^2 $ $ I > \zeta_{H2} $ $ \emptyset $

     | Show Table
    DownLoad: CSV

    Malignant steady states may exist depending on therange of the parameters. As above we chose the inflammatory stimuli $ I $ as our leading parameter and make a complete analysis of possible malignant steady states. The analysis of the existence of the malignant steady states depends crucially on the following lumped parameters,

    $ IH=2esrsβyeacyyrsβyeacyyαy,
    $
    (2.24)
    $ ζL1=2esαyrsβyeacyyαy,
    $
    (2.25)
    $ ζL2=esαy,
    $
    (2.26)
    $ ζL3=rsβyeseacyy,
    $
    (2.27)

    the last two being positive.

    Proposition 3. Two malignant steady states $ E_{L\pm} $ may exist in the following cases,

    If $ \alpha_y^2 \leq \frac{\zeta_{L3}}{4} $ then $ E_{L+} $ exists if and only if $ I > 0 $.

    If $ \frac{\zeta_{L3}}{4} < \alpha_y^2 \leq \zeta_{L3} $ then $ E_{L+} $ exists if and only if $ I \geq I_{L} $.

    If $ \zeta_{L3} < \alpha_y^2 $ then $ E_{L+} $ exists if and only if $ I > \zeta_{L2} $.

    If $ \alpha_y^2 \leq \frac{\zeta_{L3}}{4} $ then $ E_{L-} $ exists if and only if $ I \leq \zeta_{L2} $.

    If $ \frac{\zeta_{L3}}{4} < \alpha_y^2 \leq \zeta_{L3} $ then $ E_{L-} $ exists if and only if $ I_{L} \leq I \leq \zeta_{L2} $.

    If $ \zeta_{L3} < \alpha_y^2 $ then $ E_{L-} $ does not exist.

    In case of existence, $ E_{L+} = (0, 0, \bar{y}_{0L+}, \bar{y}_{1L+}, \bar{a}_{L+}, \bar{s}_{L+}) $ is given by $ \bar{y}_{0L+} = \frac{1}{2 e_s c_{yy}\alpha_y} \left(I-\zeta_{L1} + \sqrt{(\zeta_{L1}-I)^2-4 e_s \alpha_y(\zeta_{L2}-I)}\right) $, $ \bar{s}_{L+} = \alpha_y (1+c_{yy} \bar{y}_{0L+}) $, $ \bar{a}_{L+} = \frac{\beta_y \bar{y}_{0L+}}{e_a \bar{s}_{L+}} $, and $ \bar{y}_{1L+} = \frac{a_x A_x \bar{y}_{0L+}}{d_{y1}} $ whereas $ E_{L-} = (0, 0, \bar{y}_{0L-}, \bar{y}_{0L-}, \bar{a}_{L-}, \bar{s}_{L-}) $ is given by $ \bar{y}_{0L-} = \frac{1}{2 e_s c_{yy}\alpha_y} \left(I-\zeta_{L1} - \sqrt{(\zeta_{L1}-I)^2-4 e_s \alpha_y(\zeta_{L2}-I)}\right) $, $ \bar{s}_{L-} = \alpha_y (1+c_{yy} \bar{y}_{0L-}) $, $ \bar{a}_{L-} = \frac{\beta_y \bar{y}_{0L-}}{e_a \bar{s}_{L-}} $, and $ \bar{y}_{1L-} = \frac{a_x A_x \bar{y}_{0L-}}{d_{y1}} $.

    Proof. Due to symmetry in indices $ x $ and $ y $, the proof for the malignant case is equivalent to that for the hematopoietic case except index $ H $ has to be substituted by $ L $.

    The result is summarized in Table 2.

    Table 2.  Summarizing necessary and sufficient criteria for admissibility of $ E_L $. The first column conditions how $ \alpha_y $ is related to $ \zeta_{L3} $, the middle column shows the existence conditions for $ E_{L+} $ and the last column shows the existence conditions for $ E_{L\pm} $ explicitly formulated in terms of $ I $.
    For Only $ E_{L+} $ if Both $ E_{L+} $ and $ E_{L-} $ if
    $ \alpha_y^2 < \frac{\zeta_{L3}}{4} $ $ I > \zeta_{L2} $ $ I \leq \zeta_{L2} $
    $ \frac{\zeta_{L3}}{4} < \alpha_y^2 < \zeta_{L3} $ $ I > \zeta_{L2} $ $ I_{L} \leq I \leq \zeta_{L2} $
    $ \zeta_{L3} < \alpha_y^2 $ $ I > \zeta_{L2} $ $ \emptyset $

     | Show Table
    DownLoad: CSV

    The existence of a co-existing steady state

    $ E_C = (\bar{x}_{0C}, \bar{x}_{1C}, \bar{y}_{0C}, \bar{y}_{1C}, \bar{a}_{C}, \bar{s}_{C}) \, , $

    is far more cumbersome to deal with, since a wealth of sub-cases may arrive depending on various inequality-relations between the parameters. To avoid many tedious but straight forward calculations we limit ourself to the non-degenerate cases where $ \zeta_{C1} = \alpha_yc_{yx}- \alpha_xc_{xx} \neq 0 $ and $ \zeta_{C2} = \alpha_yc_{yy}- \alpha_xc_{xy} \neq 0 $.

    From Eqs (2.4a and 2.4b), a linear relation between $ \bar{x}_0 $ and $ \bar{y}_0 $ directly follows,

    $ ζC1ˉx0C+ζC2ˉy0CζC3=0,
    $
    (2.28)

    where $ \zeta_{C3} = \alpha_x-\alpha_y $. Thus, for the non-degenerate cases,

    $ ˉy0C=ζC1ζC2(ζC3ζC1ˉx0C),
    $
    (2.29)

    which geometrically corresponds to a straight line through $ \left(0, \frac{\zeta_{C3}}{\zeta_{C2}}\right) $ and $ \left(\frac{\zeta_{C3}}{\zeta_{C1}}, 0\right) $. Hence, two generic cases arrive, for $ \left(0, \frac{\zeta_{C1}}{\zeta_{C2}}\right) $ corresponding to positive slope, $ \frac{\zeta_{C1}}{\zeta_{C2}} < 0 $ corresponding to negative slope, $ \frac{\zeta_{C1}}{\zeta_{C2}} > 0 $. The first case defines a half line in the positive octahedron and in this case $ \bar{x}_{0C}\in(\max\{0, \frac{\zeta_{C3}}{\zeta_{C1}}\}; \infty) $ and $ \bar{y}_{0C}\in(\max\{0, \frac{\zeta_{C3}}{\zeta_{C2}}\}; \infty) $. The second case corresponds to either no admissible solution (if and only if $ \frac{\zeta_{C3}}{\zeta_{C2}} < 0 $ and $ \frac{\zeta_{C3}}{\zeta_{C1}} < 0 $) or a line segment in the positive octahedron which requires that $ \frac{\zeta_{C3}}{\zeta_{C2}} > 0 $ and $ \frac{\zeta_{C3}}{\zeta_{C1}} > 0 $ and in that case are $ \bar{x}_{0C}\in(0, \frac{\zeta_{C3}}{\zeta_{C1}}) $ and $ \bar{y}_{0C}\in(0, \frac{\zeta_{C3}}{\zeta_{C2}}) $. From Eq (2.4a) and (2.29),

    $ ˉsC=m1ˉx0C+m0,
    $
    (2.30)

    with $ m_0 = \alpha_x (c_{xy}\frac{\zeta_{C3}}{\zeta_{C2}}+1) $ and $ m_1 = \alpha_x (c_{xx}-c_{xy}\frac{\zeta_{C1}}{\zeta_{C2}}) $. Before continuing, it is emphasized that $ \zeta_1 $, $ \zeta_2 $, $ \zeta_3 $, $ m_0 $, and $ m_1 $ all are independent of $ I $ but may be positive, negative or in case of $ m_0 $ and $ m_1 $ zero. From Eq (2.7) it follows that a real and positive $ \bar{s} $ exist for $ (\bar{x}_{0C}, \bar{y}_{0C})\in \mathbb{R}_+ \times \mathbb{R}_+ $,

    $ ˉsC=I2es(1+1+ζ0I2(βxˉx0C+βyˉy0C))
    $
    (2.31)

    where $ \zeta_0 = \frac{4 r_s e_s}{e_a} > 0 $. Similarly, a negative real root exists. Substituting (2.29) into (2.31) give,

    $ ˉsC=I2es+(I2es)2+ζ0βyζC34e2sζC2+ζ04e2s(βxβyζC3ζC2)ˉx0C.
    $
    (2.32)

    Combining Eq (2.30) and (2.32) results in,

    $ n0I+n1ˉx0C=I2+n2+n3ˉx0C,
    $
    (2.33)

    where $ n_0 = 2e_sm_0 $, $ n_1 = 2e_sm_1 $, $ n_2 = \frac{\zeta_0 \beta_y \zeta_{C3}}{\zeta_{C2}} $ and $ n_3 = \zeta_0 \left(\beta_x-\beta_y\frac{\zeta_{C1}}{\zeta_{C2}}\right) $.

    Note that Eq (2.33) has no real solution if either of $ f(x) = n_0-I+n_1 x $ and $ g(x) = I^2+n_2+n_3 x $ are negative. Thus, if both $ f(x) $ and $ g(x) $ are positive, Eq (2.33) is equivalent to,

    $ n21x2+(2n1(n0I)n3)x+(n20n22n0I)=0,
    $
    (2.34)

    which may have up to two real positive solutions. Hence, there can be at most two coexistence steady states. More specifically,

    $ x0C+=2n1(n0I)n32n21+(2n1(n0I)n32n21)2n20n22n0In1,
    $
    (2.35)

    is positive if and only if $ f(x_{0C+}) > 0 $, $ g(x_{0C+}) > 0 $, and

    $ n20n22n0In1<0 or 2n1(n0I)n3n21<0.
    $
    (2.36)

    Similar,

    $ x0C=2n1(n0I)n32n21(2n1(n0I)n32n21)2n20n22n0In1,
    $
    (2.37)

    is positive if and only if $ f(x_{0C-}) > 0 $, $ g(x_{0C-}) > 0 $, and

    $ 2n1(n0I)n32n21>n20n22n0In1>0 and 2n1(n0I)n32n21<0.
    $
    (2.38)

    Note, some possibilities of equality signs in the inequalities are left out for simplification reasons. Equality may occur on a set of measure zero which is unlikely for a noisy biological system and including these possibilities makes the analysis much more messy. For practical purposes one may first calculate the two (possibly complex) roots $ x $ of Eq (2.34) and afterwards examine whether these are real and positive, whether $ f(x) > 0 $ and $ g(x) > 0 $, and whether the corresponding $ \bar{y}_{0C} $ calculated from Eq (2.29) is positive, thus the remaining component of $ E_{C} $ will be positive too and the steady state admissible.

    Continuing analytically is possible but becomes somehow cumbersome and instead we point out that for any choice of parameter values, there can be at most two coexistence steady states, their existence and value depending on the admissibility of $ x_{0C+} $ (Eq (2.35)) and $ x_{0C-} $ (Eq (2.37)).

    In this section we analytically and numerically examine the stability properties of the various admissible steady states of Eq (2.1) in terms of selected parameters.

    The Jacobian of the trivial steady states $ E_0 $ is a triangular matrix and four of the six eigenvalues, $ -d_{x1}, -d_{y1}, -e_s $ and $ \frac{-I e_a}{e_s} $, are negative but the two, $ \frac{r_x}{e_s} \left(I-e_s \alpha_x\right) $ and $ \frac{r_y}{e_s} \left(I-e_s \alpha_y\right) $, may be positive, negative, zero. Thus, by the Hartman-Grobman Theorem [34]

    Lemma 1. $ E_0 $ is asymptotically stable if $ I < e_s \min \{\alpha_x, \alpha_y\} $, whereas it is unstable if $ I > e_s \min \{\alpha_x, \alpha_y\} $.

    At $ E_{H\pm} $ the Jacobian for the hematopoietic states can be calculated (see Supplementary) and the resulting sixth order characteristic equation shows that $ E_{H\pm} $ are stable for

    $ ˉsH<αy(1+cyxˉx0H).
    $
    (3.1)

    However, this is not the generic case, since $ \alpha_y < \alpha_x $ (and $ c_{yx} \leq c_{xx} $), which contradicts $ \bar{s}_H = \alpha_x (1+c_{xx}\bar{x}_{0H}) $. Intensive numerical investigations shows that $ E_{H\pm} $ are unstable.

    The stability of $ E_L $ is similar to that for the hematopoietic steady state except that it is stable if

    $ ˉsL<αx(1+cxyˉy0L),
    $
    (3.2)

    which is fulfilled in the generic case, since $ \alpha_x < \alpha_y $ (and $ c_{xy} \leq c_{yy} $). This follows from $ \bar{s}_L = \alpha_y (1+c_{yy}\bar{y}_{0L}) $. The Jacobian may be found in supplementary.

    Lastly, consider the co-existing steady state. The Jacobian at $ E_{C} $ may be found in supplementary. However, it is hard to prove any result analytically and we therefore do the stability investigation numerically the in next section.

    In this section, we focus on numerical results. The default values of parameters used in Figure 2 are given in Table 3. The values are the same as given in [18].

    Figure 2.  Admissibility and stability of the steady states depending on the parameters $ I $ and $ \mathcal{C} $ for different values of $ \mathcal{R} $. Crossing a solid curve implies a change in which type of stable steady state exists i.e. trivial, malignant, hematopoietic or coexistence. Crossing a dotted curves implies the same steady state is stable in both regions but the number of steady states is changed. The stable steady states are written as subscript of $ E $ and unstable steady states are written as superscript of $ E $.
    Table 3.  Default parameter values and their lumped counterpart.
    Parameter Value Unit Parameter Value Unit
    $ r_x $ $ 8.7\cdot 10^{-4} $ day$ ^{-1} $ $ r_y $ $ 1.3\cdot 10^{-3} $ day$ ^{-1} $
    $ a_x $ $ 1.1\cdot 10^{-5} $ day$ ^{-1} $ $ a_y $ $ 1.1\cdot 10^{-5} $ day$ ^{-1} $
    $ A_x $ $ 4.7\cdot 10^{13} $ - $ A_y $ $ 4.7\cdot 10^{13} $ -
    $ d_{x_0} $ $ 2\cdot 10^{-3} $ day$ ^{-1} $ $ d_{y_0} $ $ 2\cdot 10^{-3} $ day$ ^{-1} $
    $ d_{x_1} $ 129 day$ ^{-1} $ $ d_{y_1} $ 129 day$ ^{-1} $
    $ c_{xx} $ $ 5.6\cdot 10^{-5} $ - $ c_{yx} $ $ 5.2\cdot 10^{-5} $ -
    $ c_{xy} $ $ 5.4\cdot 10^{-5} $ - $ c_{yy} $ $ 5.0\cdot 10^{-5} $ -
    $ e_s $ 2 day$ ^{-1} $ $ r_s $ $ 3\cdot 10^{-4} $ day$ ^{-1} $
    $ e_a $ $ 2\cdot 10^{9} $ day$ ^{-1} $ $ I $ $ 7 $ day
    $ \alpha_x $ $ 2.31 $ - $ \alpha_y $ $ 1.54 $ -
    $ \beta_x $ $ 5.17 \cdot 10^{8} $ - $ \beta_y $ $ 5.17 \cdot 10^{8} $ -
    $ \zeta_0 $ $ 1.2\cdot 10^{-12} $ - $ \zeta_{C1} $ $ -4.9\cdot 10^{-5} $ -
    $ \zeta_{C2} $ $ 7.4146\cdot 10^{-4} $ - $ \zeta_{C3} $ $ 0.7646 $ -
    $ n_0 $ $ 9.76 $ - $ n_1 $ $ - 0.51 $ -
    $ n_2 $ $ 0.64 $ - $ n_3 $ $ 6.61 \cdot 10^{-4} $ -
    $ \zeta_{H1} $ $ 8.65 $ - $ \zeta_{H2} $ $ 4.62 $ -
    $ \zeta_{L1} $ $ 5.18 $ - $ \zeta_{L2} $ $ 3.09 $ -
    $ \zeta_{H3} $ $ 0.69 $ - $ \zeta_{L3} $ $ 0.7646 $ -

     | Show Table
    DownLoad: CSV

    The model has been investigated for various choices of parameter values. In Figure 2, clusters of five important parameters, $ \mathcal{C} = \frac{c_{xx}}{c_{yy}} $, $ \mathcal{R} = \frac{\zeta_{H2}}{\zeta_{L2}} = \frac{\alpha_x}{\alpha_y} $ and $ I $ are considered to investigate the number of steady states and their stability. In the default case $ \mathcal{R} > 1 $ (Figure 2a), a trivial steady state always exists, and for low inflammation, i.e., $ I < \zeta_{L2} $ it is stable otherwise it is unstable. For $ I > \zeta_{L2} $, a purely malignant steady state becomes admissible. For values of $ I $ where the trivial and the malignant steady states are admissible, the malignant steady state is stable whereas the trivial steady state is unstable. An unstable hematopoietic steady state becomes admissible as $ I $ becomes larger than the threshold value $ \zeta_{H2} $, and increasing $ I $ further causes emergence of a stable co-existing steady state while the malignant steady state becomes unstable. Thus, for $ I > \zeta_{H2} $ and $ \mathcal{C} $ sufficiently small, four steady states appear namely the trivial, the hematopoietic, the malignant and the co-existing steady states where the co-existing steady state is stable and the rest are unstable. This illustrates that the co-existing steady state depends on $ I $, $ \mathcal{C} $ and $ \mathcal{R} $. Increasing $ \mathcal{C} $ from a small, initial value makes the co-existing steady state vanish and the malignant steady state becomes stable whereas the trivial and the hematopoietic steady states remain unstable. Secondly, consider the second case where $ \mathcal{R} = 1 $ implying that $ \zeta_{H2} = \zeta_{L2} $ (Figure 2b). Increasing $ I $ across this value generates an unstable hematopoietic steady state and a malignant steady state simultaneously. For $ \mathcal{C} < 1 $ the malignant steady state is unstable, and a stable coexistence steady state is created as $ I $ increase past $ \zeta_{H2} $. For $ \mathcal{C} > 1 $ no coexistence steady state is created, instead the malignant steady state is stable. Hence, for $ \mathcal{R} = 1 $, decreasing $ \mathcal{C} $ may change the topology from a stable malignant steady state to a stable coexistence steady state i.e. improving the prognosis from disease escape to disease equilibrium. The stable co-existing steady state bifurcates from the trivial steady state and remains stable until $ \mathcal{C} = 1 $. As $ \mathcal{C} $ exceeds $ 1 $, the co-existing steady state disappears, the malignant steady state becomes stable and the trivial and the hematopoietic steady state become unstable.

    In the remaining panels, $ \mathcal{R} < 1 $, which implies that a stable hematopoietic steady state is created as the first transition to appear when increasing $ I $ from low values past the threshold value $ \zeta_{H2} $. Simultaneously, the trivial steady state becomes unstable. In Figure 2c where $ \mathcal{R} = 0.97 $ the hematopoietic steady state remains stable for low values of $ \mathcal{C} $ until $ I $ passes a threshold value where a stable coexistence steady state is created leaving the hematopoietic steady state unstable.

    For larger values of $ \mathcal{C} $ there is no coexistence steady state. Instead, as $ I $ is increased, a region of bistability appears with a stable hematopoietic steady state and a stable malignant steady state. Increasing $ I $ further the hematopoietic steady state becomes unstable. Hence, to reduce disease load, in the case of $ \mathcal{R} < 1 $, and large values of $ \mathcal{C} $ and $ I $, it may be optimal treatment to reduce the $ \mathcal{C} $ value prior to reducing the inflammatory level to avoid being stuck in the bassin of attraction of the malignant steady state.

    In Figure 2d where $ \mathcal{R} = 0.93 $, the coexistence steady state no longer appears, the region of bistability has shrunk and a hematopoietic stable steady state is more dominant.

    In Figure 2e and f, $ \mathcal{R} $ is decreased to $ 0.77 $ and $ 0.5 $ respectively, and the bistability region is no longer visible. For $ I > \zeta_{H2} $ a hematopoietic steady state is the only stable steady state. Figure 2 indicates that reducing $ \mathcal{C} $ and $ \mathcal{R} $ should be targets of intervention. A reduction of $ I $ may improve prognosis as well, for example for parameter values as in 2c.

    A mechanism-based model published in [5] - the Cancitis model - describing the interaction of the hematopoietic cells, malignant cells and inflammation is analysed here. A thorough mathematical investigation of the model is presented in this paper which did not appear previously. We conducted an analytical analysis of the steady states and showed that four kinds of steady states may exist i.e. trivial, hematopoietic, malignant and co-existing steady states. We characterized the stability of each of these steady states and identified transitions conditions in the number of steady states and in their stability. Trivial, hematopoietic, malignant and coexistence steady states all appear for some parameter values. The steady states are highly relevant as all trajectories appear to approach a steady state after some time - see Figure 3. The case of bistability is visualized in the bottom right panel of Figure 3, with the basin of attraction shown in the $ (x_0, y_0) $-plane using initial condition $ (x_1, y_1, a, s) = (4\times 10^{11}, 4\times 10^{11}, 600, 2) $. The initial conditions for $ x_0 $ and $ y_0 $ are varied in a range $ 1-10^{5} $. The malignant steady state has a large bassin of attraction (region (i)), while region (ii) marks the bassin of attraction for the hematopoietic steady state.

    Figure 3.  The first three panels illustrate that when a unique, stable steady state exists, it is globally attracting (based on a numerical argument). $ U(t) $ denotes the solution of the six-dimensional model 2.1. In the top left panel, $ \frac{||U(t)-E_{H}||}{||U(0)-E_{H}||} $ is plotted against time for three different initial conditions. It corresponds to the region where $ E_H $ is stable with $ \mathcal{C} = 0.8 $, $ \mathcal{R} = 0.97 $ and $ I = 6 $. $ \frac{||U(t)-E_{H}||}{||U(0)-E_{H}||} $ tending to zero for large time implies that $ U(t) $ is close to $ E_H $ for large time. The top right panel shows the stability of $ E_L $ with $ \mathcal{C} = 0.2 $, $ \mathcal{R} = 1.5 $ and $ I = 4 $. The bottom left panel shows the stability of $ E_C $ with $ \mathcal{C} = 0.1 $, $ \mathcal{R} = 1.5 $ and $ I = 7 $. The bottom right panel corresponds to bi-stability of $ E_H $ and $ E_L $ with $ \mathcal{C} = 1.4 $, $ \mathcal{R} = 0.97 $. The solution to the 6D model is projected onto the $ x_0 $ and $ y_0 $ plane. Region $ (i) $ denotes the set of initial conditions with trajectories converging to $ E_L $ whereas region $ (ii) $ denotes that trajectories converge to $ E_H $. Black circles show four steady states, $ E_0 $, $ E_H $, $ E_L $ and $ E_C $, where filled circle shows stable steady states and empty circle shows unstable steady states.

    The intuitive interpretation in most bio-medical literature attributes the main cause for cancer development to the frequency of stem cell division. Another main cause is the regulatory feedback that allows stem cells residing in niche to further divide into blood cell required in blood stream. Our investigation is in agreement with this perception and quantifies this intuitive concept. Furthermore, it shows that stem cell population is important to target in treatment to prevent disease progression.

    In [14] and [15] a model without immune interaction is presented. The authors discuss a fraction similar to $ \mathcal{R} $ and show that it is important for the dynamics of the system. It has been shown [15] that the leukemic cell load can be temporarily reduced if the growth of HSC is larger than that of leukemic cells for cytokine-dependent AML.

    It is generally assumed that $ c_{yy} \leq c_{xx} $ since malignant cells might be less sensitive to environmental crowding [22] and [24]. The ratio $ \mathcal{C} $ of inhibition of the hematopoietic relative to malignant cells is one of several important prognostic markers. For large values of $ I $, bi-stable and mono-stable regions depend upon $ \mathcal{C} $. It can be observed in Figure 2 that for small values of $ \mathcal{C} $, i.e., $ c_{yy} \geq c_{xx} $, either the hematopoietic steady state is stable or the co-existing steady state is stable which can be interpreted as a good prognosis. However, large values of $ \mathcal{C} $ may lead to a worse situation, e.g. in one case, the malignant steady state is stable or there exists bi-stability of the hematopoietic and the malignant steady states (see Figure 2c). In addition to the ratio of inhibitive niche feedback, the ratio $ \mathcal{R} $ is also important to consider, since it determines how robust the hematopoietic condition may be and how disastrously a potential blood cancer disease will develop. Thus for $ \mathcal{R} > 1 $ we have a more serious situation than for $ \mathcal{R} < 1 $ showing that if this reproduction ratio exceeds the threshold $ \mathcal{R}_0 = 1 $, it is more disastrous than if it is below $ \mathcal{R}_0 $.

    The $ JAK2 $V617F allele burden is expected to increase due to the expansion of malignant cells. The $ JAK2 $V617F allele burden is interpreted as the ratio of malignant cells to the total number of mature cells. The model predicted $ JAK2 $V617F allele burden is shown in Figure 4 for the region where $ E_C $ is stable. Perturbation of a parameter may improve or impair prognosis when the coexistence point is the stable attractor. The top panel of Figure 4, shows that decreasing $ \mathcal{C} $ and $ \mathcal{R} $ improve prognosis by lowering the allele burden. Contrarily, increasing $ I $, causes a decay in allele burden. This suggests that inflammatory inhibitors could counteract treatments in this case. In other cases, increasing $ I $ typically leads to a worse prognosis, considering Figure 2.

    Figure 4.  Allele burden (the ratio of $ \bar y_{1c} $ to the total number of $ \bar x_{1c} $ and $ \bar y_{1c} $) at the steady state for the region where the co-existing steady state is stable. On the top, left and right panels show that by increasing $ \mathcal{C} $ and $ \mathcal{R} $, allele burden also increases. On the contrary, increasing $ I $ reduces the allele burden. In the top panel $ \mathcal{R} = 1.5 $ and $ I = 7 $, in the top right, $ \mathcal{C} = 0.1 $ and $ I = 7 $ and in the bottom panel, $ \mathcal{R} = 1.5 $ and $ \mathcal{C} = 0.1 $.

    The model presented here may inform clinical practice to make group specific treatment protocols with particular focus on the inflammatory components which may accelerate or dampen the disease progression. Interventions should address decreasing $ \mathcal{C} $ and $ \mathcal{R} $ and potentially $ I $ but the latter depends on the remaining parameter values as adverse effects may be observed.

    No conflict of interest.

    Stability analysis of Steady states:

    At $ E_{H\pm} $ the Jacobian of the purely hematopoietic steady state becomes,

    $ JEH=[a110a1300a16a21a22000000a3300000a43a4400a51a52a53a54a55a560000a65a66]
    $
    (6.1)

    where

    $ a_{11} = r_x \left(\frac{\bar{s}_{H}}{(1+c_{xx} \bar{x}_{0H})^2}-\alpha_x\right) $,

    $ a_{13} = -\frac{r_x c_{xy} \bar{s}_{H} \bar{x}_{0H}}{(1+c_{xx} \bar{x}_{0H})^2} $,

    $ a_{16} = \frac{r_x \bar{x}_{0H}}{(1+c_{xx} \bar{x}_{0H})} $,

    $ a_{21} = a_x A_x $,

    $ a_{22} = -d_{x1} $,

    $ a_{33} = r_y \left(\frac{\bar{s}_{H}}{1+c_{yx} \bar{x}_{0H}}-\alpha_y\right) $,

    $ a_{43} = a_y A_y $,

    $ a_{44} = -d_{y1} $,

    $ a_{51} = d_{x0} $,

    $ a_{52} = d_{x1} $,

    $ a_{53} = d_{y0} $,

    $ a_{54} = d_{y1} $,

    $ a_{55} = -e_a \bar{s}_{H} $,

    $ a_{56} = -e_a \bar{a}_{H} $,

    $ a_{65} = r_s $,

    $ a_{66} = -e_s $,

    and rest of the elements of $ J_{E_H} $ are zero.

    At $ E_{L\pm} $ the Jacobian of the purely malignant steady state.

    $ JEL=[a1100000a21a220000a310a3300a3600a43a4400a51a52a53a54a55a560000a65a66]
    $
    (6.2)

    where

    $ a_{11} = r_x\left(\frac{ \bar{s}_{L}}{1+c_{xy}\bar{y}_{0L}}-\alpha_x\right) $,

    $ a_{21} = a_x A_x $,

    $ a_{22} = -d_{x1} $,

    $ a_{31} = -\frac{r_y c_{yx}\bar{s}_{L} \bar{y}_{0L}}{(1+c_{yy} \bar{y}_{0L})^2} $,

    $ a_{33} = r_y \left(\frac{\bar{s}_{L}}{(1+c_{yy}\bar{y}_{0L})^2}-\alpha_y\right) $,

    $ a_{36} = \frac{r_y \bar{y}_{0L}}{1+c_{yy}\bar{y}_{0L}} $.

    $ a_{43} = a_y A_y $.

    $ a_{44} = -d_{y1} $.

    $ a_{51} = d_{x0} $.

    $ a_{52} = d_{x1} $.

    $ a_{53} = d_{y0} $.

    $ a_{54} = d_{y1} $.

    $ a_{55} = -e_a \bar{s}_{L} $.

    $ a_{56} = -e_a \bar{a}_{L} $.

    $ a_{65} = r_s $.

    $ a_{66} = -e_s $

    and rest of the elements of array are zero.

    At $ E_{C\pm} $ the Jacobian of the co-existing steady state becomes,

    $ JEC=[a110a1300a16a21a220000a310a3300a3600a43a4400a51a52a53a54a55a560000a65a66]
    $
    (6.3)

    where

    $ a_{11} = r_x \left(\frac{\bar{s}_C}{(1+c_{xx}\bar{x}_{0C}+c_{xy} \bar{y}_{0C})^2}-\alpha_x \right) $,

    $ a_{13} = -\frac{r_x c_{xy} \bar{s}_C \bar{x}_{0C}}{(1+c_{xx}\bar{x}_{0C}+c_{xy}\bar{y}_{0C})^2} $,

    $ a_{16} = \frac{r_x \bar{x}_{0C}}{(1+c_{xx}\bar{x}_{0C}+c_{xy} \bar{y}_{0C})} $,

    $ a_{21} = a_x A_x $,

    $ a_{22} = -d_{x1} $,

    $ a_{31} = -\frac{r_y c_{yx} \bar{s}_C \bar{y}_{0C}}{(1+c_{yx}\bar{x}_{0C}+c_{yy}\bar{y}_{0C})^2} $,

    $ a_{33} = r_y \left(\frac{\bar{s}_C}{(1+c_{yx}\bar{x}_{0C}+c_{yy} \bar{y}_{0C})^2}-\alpha_y \right) $,

    $ a_{36} = \frac{r_y \bar{y}_{0C}}{(1+c_{yx}\bar{x}_{0C}+c_{yy} \bar{y}_{0C})} $,

    $ a_{43} = a_y A_y $,

    $ a_{44} = -d_{y1} $,

    $ a_{51} = d_{x0} $,

    $ a_{52} = d_{x1} $,

    $ a_{53} = d_{y0} $,

    $ a_{54} = d_{y1} $,

    $ a_{55} = -e_a \bar{s}_C $,

    $ a_{56} = -e_a \bar{a}_C $,

    $ a_{65} = r_s $,

    $ a_{66} = -e_s $

    and rest of the elements of the $ J_{E_C} $ are zero.

    [1] Banks S, Dinges DF (2007) Behavioral and physiological consequences of sleep restriction. J Clin Sleep Med 3: 519-528.
    [2] Van Dongen HP, Maislin G, Mullington JM, et al. (2003) The cumulative cost of additional wakefulness: dose-response effects on neurobehavioral functions and sleep physiology from chronic sleep restriction and total sleep deprivation. Sleep 26: 117-126.
    [3] Knutson KL, Spiegel K, Penev P, et al. (2007) The metabolic consequences of sleep deprivation. Sleep Med Rev 11: 163-178. doi: 10.1016/j.smrv.2007.01.002
    [4] Dixit A, Mittal T (2015) Executive Functions are not Affected by 24 Hours of Sleep Deprivation: A Color-Word Stroop Task Study. Indian J Psychol Med 37: 165-168. doi: 10.4103/0253-7176.155615
    [5] Mignot E (2008) Why we sleep: the temporal organization of recovery. PLoS Biol 6: e106. doi: 10.1371/journal.pbio.0060106
    [6] McCormick DA, Bal T (1997) Sleep and arousal: thalamocortical mechanisms. Annu Rev Neurosci 20: 185-215. doi: 10.1146/annurev.neuro.20.1.185
    [7] Pace-Schott EF, Hobson JA (2002) The neurobiology of sleep: genetics, cellular physiology and subcortical networks. Nat Rev Neurosci 3: 591-605. doi: 10.1038/nrn895
    [8] Villablanca JR (2004) Counterpointing the functional role of the forebrain and of the brainstem in the control of the sleep-waking system. J Sleep Res 13: 179-208. doi: 10.1111/j.1365-2869.2004.00412.x
    [9] Krueger J CL, Rector D (2009) Cytokines and other neuromodulators. Stickgold R, Walker M (eds) The neuroscience of sleep.
    [10] Porkka-Heiskanen T (2011) Methylxanthines and sleep. Fredholm BB (ed) Methylxanthines, handbook of experimental pharmacology 331-348.
    [11] Krueger JM, Rector DM, Roy S, et al. (2008) Sleep as a fundamental property of neuronal assemblies. Nat Rev Neurosci 9: 910-919. doi: 10.1038/nrn2521
    [12] Vyazovskiy VV, Olcese U, Hanlon EC, et al. (2011) Local sleep in awake rats. Nature 472: 443-447. doi: 10.1038/nature10009
    [13] Llinas RR, Steriade M (2006) Bursting of thalamic neurons and states of vigilance. J Neurophysiol 95: 3297-3308. doi: 10.1152/jn.00166.2006
    [14] Coulon P, Budde T, Pape HC (2012) The sleep relay--the role of the thalamus in central and decentral sleep regulation. Pflugers Arch 463: 53-71. doi: 10.1007/s00424-011-1014-6
    [15] Steriade M MR (1990) Brainstem control of wakefulness and sleep. Plenum, New York.
    [16] Haas HL L, JS (2012) Waking with the hypothalamus. Pflugers Arch 463: 31-42. doi: 10.1007/s00424-011-0996-4
    [17] Basheer R SR, Thakkar MM, McCarley RW (2004) Adenosine and sleep-wake regulation. Progr Neurobiol 73: 379-396. doi: 10.1016/j.pneurobio.2004.06.004
    [18] Obal F, Jr., Krueger JM (2003) Biochemical regulation of non-rapid-eye-movement sleep. Front Biosci 8: d520-550. doi: 10.2741/1033
    [19] De Sarro G, Gareri P, Sinopoli VA, et al. (1997) Comparative, behavioural and electrocortical effects of tumor necrosis factor-alpha and interleukin-1 microinjected into the locus coeruleus of rat. Life Sci 60: 555-564. doi: 10.1016/S0024-3205(96)00692-3
    [20] Manfridi A, Brambilla D, Bianchi S, et al. (2003) Interleukin-1beta enhances non-rapid eye movement sleep when microinjected into the dorsal raphe nucleus and inhibits serotonergic neurons in vitro. Eur J Neurosci 18: 1041-1049. doi: 10.1046/j.1460-9568.2003.02836.x
    [21] De A, Churchill L, Obal F, Jr., et al. (2002) GHRH and IL1beta increase cytoplasmic Ca(2+) levels in cultured hypothalamic GABAergic neurons. Brain Res 949: 209-212. doi: 10.1016/S0006-8993(02)03157-8
    [22] Huber R, Tononi G, Cirelli C (2007) Exploratory behavior, cortical BDNF expression, and sleep homeostasis. Sleep 30: 129-139.
    [23] Porkka-Heiskanen T, Alanko L, Kalinchuk A, et al. (2002) Adenosine and sleep. Sleep Med Rev 6: 321-332. doi: 10.1053/smrv.2001.0201
    [24] Oishi Y, Huang ZL, Fredholm BB, et al. (2008) Adenosine in the tuberomammillary nucleus inhibits the histaminergic system via A1 receptors and promotes non-rapid eye movement sleep. Proc Natl Acad Sci U S A 105: 19992-19997. doi: 10.1073/pnas.0810926105
    [25] Rosenberg PA, Li Y, Le M, et al. (2000) Nitric oxide-stimulated increase in extracellular adenosine accumulation in rat forebrain neurons in culture is associated with ATP hydrolysis and inhibition of adenosine kinase activity. J Neurosci 20: 6294-6301.
    [26] MM H (2011) Thalamocortical dynamics of sleep: roles of purinergic neuromodulation. Semin Cell Dev Biol 22: 245-251. doi: 10.1016/j.semcdb.2011.02.008
    [27] Steriade M, McCormick DA, Sejnowski TJ (1993) Thalamocortical oscillations in the sleeping and aroused brain. Science 262: 679-685. doi: 10.1126/science.8235588
    [28] Brown RE, Basheer R, McKenna JT, et al. (2012) Control of sleep and wakefulness. Physiol Rev 92: 1087-1187. doi: 10.1152/physrev.00032.2011
    [29] Rechtschaffen A KA (1968) A manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects. National Institue of Health Publication Washington, DC: NIH US Goverment Printing Office
    [30] Jeanneret PR, Webb WB (1963) Strength of grip on arousal from full night's sleep. Percept Mot Skills 17: 759-761. doi: 10.2466/pms.1963.17.3.759
    [31] Tassi P, Muzet A (2000) Sleep inertia. Sleep Med Rev 4: 341-353. doi: 10.1053/smrv.2000.0098
    [32] Klemm WR (2011) Why does rem sleep occur? A wake-up hypothesis. Front Syst Neurosci 5: 73.
    [33] Roffwarg HP, Muzio JN, Dement WC (1966) Ontogenetic development of the human sleep-dream cycle. Science 152: 604-619. doi: 10.1126/science.152.3722.604
    [34] Endo T, Roth C, Landolt HP, et al. (1998) Selective REM sleep deprivation in humans: effects on sleep and sleep EEG. Am J Physiol 274: R1186-1194.
    [35] Barone DA, Krieger AC (2014) Muscle Tone Control of REM Sleep. REM Sleep: Characteristics, Disorders, and Physiological Effects / Editor: Chelsea L Saylor
    [36] Kamphuis J, Lancel M, Koolhaas JM, et al. (2015) Deep sleep after social stress: NREM sleep slow-wave activity is enhanced in both winners and losers of a conflict. Brain Behav Immun 47:149-54. doi: 10.1016/j.bbi.2014.12.022
    [37] Benington JH, Heller HC (1995) Restoration of brain energy metabolism as the function of sleep. Prog Neurobiol 45: 347-360. doi: 10.1016/0301-0082(94)00057-O
    [38] H. Blake RWG (1937) Brain potentials during sleep. Am J Physiol 119 692-703.
    [39] Friedman L, Bergmann BM, Rechtschaffen A (1979) Effects of sleep deprivation on sleepiness, sleep intensity, and subsequent sleep in the rat. Sleep 1: 369-391.
    [40] Tobler I, Borbely AA (1986) Sleep EEG in the rat as a function of prior waking. Electroencephalogr Clin Neurophysiol 64: 74-76. doi: 10.1016/0013-4694(86)90044-1
    [41] Dijk DJ, Beersma DG, Daan S (1987) EEG power density during nap sleep: reflection of an hourglass measuring the duration of prior wakefulness. J Biol Rhythms 2: 207-219. doi: 10.1177/074873048700200304
    [42] Franken P, Tobler I, Borbely AA (1991) Sleep homeostasis in the rat: simulation of the time course of EEG slow-wave activity. Neurosci Lett 130: 141-144. doi: 10.1016/0304-3940(91)90382-4
    [43] Lancel M, van Riezen H, Glatt A (1992) The time course of sigma activity and slow-wave activity during NREMS in cortical and thalamic EEG of the cat during baseline and after 12 hours of wakefulness. Brain Res 596: 285-295. doi: 10.1016/0006-8993(92)91559-W
    [44] Huber R, Deboer T, Tobler I (2000) Effects of sleep deprivation on sleep and sleep EEG in three mouse strains: empirical data and simulations. Brain Res 857: 8-19. doi: 10.1016/S0006-8993(99)02248-9
    [45] Sanchez-Vives MV, Mattia M (2014) Slow wave activity as the default mode of the cerebral cortex. Arch Ital Biol 152: 147-155.
    [46] Meerlo P, Pragt BJ, Daan S (1997) Social stress induces high intensity sleep in rats. Neurosci Lett 225: 41-44. doi: 10.1016/S0304-3940(97)00180-8
    [47] Meerlo P, de Bruin EA, Strijkstra AM, et al. (2001) A social conflict increases EEG slow-wave activity during subsequent sleep. Physiol Behav 73: 331-335. doi: 10.1016/S0031-9384(01)00451-6
    [48] Berger RJ, Phillips NH (1995) Energy conservation and sleep. Behav Brain Res 69: 65-73. doi: 10.1016/0166-4328(95)00002-B
    [49] Berger RJ (1984) Slow wave sleep, shallow torpor and hibernation: homologous states of diminished metabolism and body temperature. Biol Psychol 19: 305-326. doi: 10.1016/0301-0511(84)90045-0
    [50] Siegel JM (2009) Sleep viewed as a state of adaptive inactivity. Nat Rev Neurosci 10: 747-753. doi: 10.1038/nrn2697
    [51] Rechtschaffen A (1998) Current perspectives on the function of sleep. Perspect Biol Med 41: 359-390. doi: 10.1353/pbm.1998.0051
    [52] Zepelin H, Rechtschaffen A (1974) Mammalian sleep, longevity, and energy metabolism. Brain Behav Evol 10: 425-470. doi: 10.1159/000124330
    [53] Horne J (2002) Why sleep? Biologist (London) 49: 213-216.
    [54] Schmidt MH (2014) The energy allocation function of sleep: A unifying theory of sleep, torpor, and continuous wakefulness. Neurosci Biobehav Rev 47c: 122-153.
    [55] Adam K (1980) Sleep as a restorative process and a theory to explain why. Prog Brain Res 53: 289-305. doi: 10.1016/S0079-6123(08)60070-9
    [56] Oswald I (1980) Sleep as restorative process: human clues. Prog Brain Res 53: 279-288. doi: 10.1016/S0079-6123(08)60069-2
    [57] Landgraf D, Shostak A, Oster H (2012) Clock genes and sleep. Pflugers Arch 463: 3-14. doi: 10.1007/s00424-011-1003-9
    [58] Wisor JP (2012) A metabolic-transcriptional network links sleep and cellular energetics in the brain. Pflugers Arch 463: 15-22. doi: 10.1007/s00424-011-1030-6
    [59] Cirelli C, Gutierrez CM, Tononi G (2004) Extensive and divergent effects of sleep and wakefulness on brain gene expression. Neuron 41: 35-43. doi: 10.1016/S0896-6273(03)00814-6
    [60] Mackiewicz M, Shockley KR, Romer MA, et al. (2007) Macromolecule biosynthesis: a key function of sleep. Physiol Genomics 31: 441-457. doi: 10.1152/physiolgenomics.00275.2006
    [61] Cirelli C (2006) Cellular consequences of sleep deprivation in the brain. Sleep Med Rev 10: 307-321. doi: 10.1016/j.smrv.2006.04.001
    [62] Clugston GA, Garlick PJ (1982) The response of protein and energy metabolism to food intake in lean and obese man. Hum Nutr Clin Nutr 36c: 57-70.
    [63] Clugston GA, Garlick PJ (1982) The response of whole-body protein turnover to feeding in obese subjects given a protein-free, low-energy diet for three weeks. Hum Nutr Clin Nutr 36: 391-397.
    [64] Golden MH, Waterlow JC (1977) Total protein synthesis in elderly people: a comparison of results with [15N]glycine and [14C]leucine. Clin Sci Mol Med 53: 277-288.
    [65] Horne JA (1980) Sleep and body restitution. Experientia 36: 11-13. doi: 10.1007/BF02003942
    [66] Meddis R (1975) On the function of sleep. Anim Behav 23: 676-691. doi: 10.1016/0003-3472(75)90144-X
    [67] Rial RV, Nicolau MC, Gamundi A, et al. (2007) The trivial function of sleep. Sleep Med Rev 11: 311-325. doi: 10.1016/j.smrv.2007.03.001
    [68] Webb WB (1974) Sleep as an adaptive response. Percept Mot Skills 38: 1023-1027. doi: 10.2466/pms.1974.38.3c.1023
    [69] Villafuerte G, Miguel-Puga A, Rodriguez EM, et al. (2015) Sleep deprivation and oxidative stress in animal models: a systematic review. Oxid Med Cell Longev 2015: 234952.
    [70] Komoda Y, Honda K, Inoue S (1990) SPS-B, a physiological sleep regulator, from the brainstems of sleep-deprived rats, identified as oxidized glutathione. Chem Pharm Bull (Tokyo) 38: 2057-2059. doi: 10.1248/cpb.38.2057
    [71] Honda K, Komoda Y, Inoue S (1994) Oxidized glutathione regulates physiological sleep in unrestrained rats. Brain Res 636: 253-258. doi: 10.1016/0006-8993(94)91024-3
    [72] Kimura M, Kapas L, Krueger JM (1998) Oxidized glutathione promotes sleep in rabbits. Brain Res Bull 45: 545-548. doi: 10.1016/S0361-9230(97)00441-3
    [73] Krueger JM, Obal F, Jr., Fang J (1999) Why we sleep: a theoretical view of sleep function. Sleep Med Rev 3: 119-129. doi: 10.1016/S1087-0792(99)90019-9
    [74] Basner M, Rao H, Goel N, et al. (2013) Sleep deprivation and neurobehavioral dynamics. Curr Opin Neurobiol 23: 854-863. doi: 10.1016/j.conb.2013.02.008
    [75] Hennevin E, Huetz C, Edeline JM (2007) Neural representations during sleep: from sensory processing to memory traces. Neurobiol Learn Mem 87: 416-440. doi: 10.1016/j.nlm.2006.10.006
    [76] Tononi G, Cirelli C (2014) Sleep and the price of plasticity: from synaptic and cellular homeostasis to memory consolidation and integration. Neuron 81: 12-34. doi: 10.1016/j.neuron.2013.12.025
    [77] Xie L, Kang H, Xu Q, et al. (2013) Sleep drives metabolite clearance from the adult brain. Science 342: 373-377. doi: 10.1126/science.1241224
    [78] Mendelsohn AR, Larrick JW (2013) Sleep facilitates clearance of metabolites from the brain: glymphatic function in aging and neurodegenerative diseases. Rejuvenation Res 16: 518-523. doi: 10.1089/rej.2013.1530
    [79] Spira AP, Gamaldo AA, An Y, et al. (2013) Self-reported sleep and beta-amyloid deposition in community-dwelling older adults. JAMA Neurol 70: 1537-1543.
    [80] Hahn EA, Wang HX, Andel R, et al. (2014) A change in sleep pattern may predict Alzheimer disease. Am J Geriatr Psychiatry 22: 1262-1271. doi: 10.1016/j.jagp.2013.04.015
    [81] Lim AS, Yu L, Kowgier M, et al. (2013) Modification of the relationship of the apolipoprotein E epsilon4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep. JAMA Neurol 70: 1544-1551. doi: 10.1001/jamaneurol.2013.4215
    [82] Ambrosini MV, Giuditta A (2001) Learning and sleep: the sequential hypothesis. Sleep Med Rev 5: 477-490. doi: 10.1053/smrv.2001.0180
    [83] Ribeiro S, Mello CV, Velho T, et al. (2002) Induction of hippocampal long-term potentiation during waking leads to increased extrahippocampal zif-268 expression during ensuing rapid-eye-movement sleep. J Neurosci 22: 10914-10923.
    [84] Ribeiro S, Gervasoni D, Soares ES, et al. (2004) Long-lasting novelty-induced neuronal reverberation during slow-wave sleep in multiple forebrain areas. PLoS Biol 2: E24. doi: 10.1371/journal.pbio.0020024
    [85] Huber R, Ghilardi MF, Massimini M, et al. (2004) Local sleep and learning. Nature 430: 78-81. doi: 10.1038/nature02663
    [86] Walker MP, Stickgold R (2004) Sleep-dependent learning and memory consolidation. Neuron 44: 121-133. doi: 10.1016/j.neuron.2004.08.031
    [87] Stickgold R, Walker MP (2005) Memory consolidation and reconsolidation: what is the role of sleep? Trends Neurosci 28: 408-415. doi: 10.1016/j.tins.2005.06.004
    [88] Maquet P, Schwartz S, Passingham R, et al. (2003) Sleep-related consolidation of a visuomotor skill: brain mechanisms as assessed by functional magnetic resonance imaging. J Neurosci 23: 1432-1440.
    [89] Tononi G, Cirelli C (2006) Sleep function and synaptic homeostasis. Sleep Med Rev 10: 49-62. doi: 10.1016/j.smrv.2005.05.002
    [90] Kavanau JL (1997) Memory, sleep and the evolution of mechanisms of synaptic efficacy maintenance. Neuroscience 79: 7-44. doi: 10.1016/S0306-4522(96)00610-0
    [91] Stickgold R (2006) Neuroscience: a memory boost while you sleep. Nature 444: 559-560. doi: 10.1038/nature05309
    [92] Eichenbaum H (2007) To sleep, perchance to integrate. Proc Natl Acad Sci U S A 104: 7317-7318. doi: 10.1073/pnas.0702503104
    [93] Fenn KM, Nusbaum HC, Margoliash D (2003) Consolidation during sleep of perceptual learning of spoken language. Nature 425: 614-616. doi: 10.1038/nature01951
    [94] Ferrara M, Iaria G, De Gennaro L, et al. (2006) The role of sleep in the consolidation of route learning in humans: a behavioural study. Brain Res Bull 71: 4-9. doi: 10.1016/j.brainresbull.2006.07.015
    [95] Peigneux P, Laureys S, Fuchs S, et al. (2004) Are spatial memories strengthened in the human hippocampus during slow wave sleep? Neuron 44: 535-545. doi: 10.1016/j.neuron.2004.10.007
    [96] Gottselig JM, Hofer-Tinguely G, Borbely AA, et al. (2004) Sleep and rest facilitate auditory learning. Neuroscience 127: 557-561. doi: 10.1016/j.neuroscience.2004.05.053
    [97] Peters KR, Smith V, Smith CT (2007) Changes in sleep architecture following motor learning depend on initial skill level. J Cogn Neurosci 19: 817-829. doi: 10.1162/jocn.2007.19.5.817
    [98] Ellenbogen JM, Payne JD, Stickgold R (2006) The role of sleep in declarative memory consolidation: passive, permissive, active or none? Curr Opin Neurobiol 16: 716-722. doi: 10.1016/j.conb.2006.10.006
    [99] Ellenbogen JM, Hulbert JC, Stickgold R, et al. (2006) Interfering with theories of sleep and memory: sleep, declarative memory, and associative interference. Curr Biol 16: 1290-1294. doi: 10.1016/j.cub.2006.05.024
    [100] Roth TC, 2nd, Rattenborg NC, Pravosudov VV (2010) The ecological relevance of sleep: the trade-off between sleep, memory and energy conservation. Philos Trans R Soc Lond B Biol Sci 365: 945-959. doi: 10.1098/rstb.2009.0209
    [101] Fogel SMS, C. T. (2006) Declarative learningdependent changes in theta power during REM sleep. Sleep: A375-A375.
    [102] Born J, Rasch B, Gais S (2006) Sleep to remember. Neuroscientist 12: 410-424. doi: 10.1177/1073858406292647
    [103] Wyatt RJ, Fram DH, Kupfer DJ, et al. (1971) Total prolonged drug-induced REM sleep suppression in anxious-depressed patients. Arch Gen Psychiatry 24: 145-155. doi: 10.1001/archpsyc.1971.01750080049007
    [104] Siegel JM (2001) The REM sleep-memory consolidation hypothesis. Science 294: 1058-1063. doi: 10.1126/science.1063049
    [105] Rasch B, Pommer J, Diekelmann S, et al. (2009) Pharmacological REM sleep suppression paradoxically improves rather than impairs skill memory. Nat Neurosci 12: 396-397. doi: 10.1038/nn.2206
    [106] Irwin MR (2015) Why sleep is important for health: a psychoneuroimmunology perspective. Annu Rev Psychol 66: 143-172. doi: 10.1146/annurev-psych-010213-115205
    [107] Baglioni C, Battagliese G, Feige B, et al. (2011) Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord 135: 10-19. doi: 10.1016/j.jad.2011.01.011
    [108] Dryman A, Eaton WW (1991) Affective symptoms associated with the onset of major depression in the community: findings from the US National Institute of Mental Health Epidemiologic Catchment Area Program. Acta Psychiatr Scand 84: 1-5. doi: 10.1111/j.1600-0447.1991.tb01410.x
    [109] Lee E, Cho HJ, Olmstead R, et al. (2013) Persistent sleep disturbance: a risk factor for recurrent depression in community-dwelling older adults. Sleep 36: 1685-1691.
    [110] Cho HJ, Lavretsky H, Olmstead R, et al. (2008) Sleep disturbance and depression recurrence in community-dwelling older adults: a prospective study. Am J Psychiatry 165: 1543-1550. doi: 10.1176/appi.ajp.2008.07121882
    [111] Jaussent I, Bouyer J, Ancelin ML, et al. (2011) Insomnia and daytime sleepiness are risk factors for depressive symptoms in the elderly. Sleep 34: 1103-1110.
    [112] Manber R, Edinger JD, Gress JL, et al. (2008) Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia. Sleep 31: 489-495.
    [113] Giedke H, Schwarzler F (2002) Therapeutic use of sleep deprivation in depression. Sleep Med Rev 6: 361-377. doi: 10.1016/S1087-0792(02)90235-2
    [114] Grozinger M, Kogel P, Roschke J (2002) Effects of REM sleep awakenings and related wakening paradigms on the ultradian sleep cycle and the symptoms in depression. J Psychiatr Res 36: 299-308. doi: 10.1016/S0022-3956(02)00022-5
    [115] Killgore WD, Kamimori GH, Balkin TJ (2011) Caffeine protects against increased risk-taking propensity during severe sleep deprivation. J Sleep Res 20: 395-403. doi: 10.1111/j.1365-2869.2010.00893.x
    [116] McKenna BS, Dickinson DL, Orff HJ, et al. (2007) The effects of one night of sleep deprivation on known-risk and ambiguous-risk decisions. J Sleep Res 16: 245-252. doi: 10.1111/j.1365-2869.2007.00591.x
    [117] Venkatraman V, Chuah YM, Huettel SA, et al. (2007) Sleep deprivation elevates expectation of gains and attenuates response to losses following risky decisions. Sleep 30: 603-609.
    [118] Killgore WD, Killgore DB, Day LM, et al. (2007) The effects of 53 hours of sleep deprivation on moral judgment. Sleep 30: 345-352.
    [119] Trinder J, Waloszek J, Woods MJ, et al. (2012) Sleep and cardiovascular regulation. Pflugers Arch 463: 161-168. doi: 10.1007/s00424-011-1041-3
    [120] Barone DA, Krieger AC (2013) Stroke and obstructive sleep apnea: a review. Curr Atheroscler Rep 15: 334. doi: 10.1007/s11883-013-0334-8
    [121] Mullington JM, Haack M, Toth M, et al. (2009) Cardiovascular, inflammatory, and metabolic consequences of sleep deprivation. Prog Cardiovasc Dis 51: 294-302. doi: 10.1016/j.pcad.2008.10.003
    [122] Vgontzas AN, Fernandez-Mendoza J, Liao D, et al. (2013) Insomnia with objective short sleep duration: the most biologically severe phenotype of the disorder. Sleep Med Rev 17: 241-254. doi: 10.1016/j.smrv.2012.09.005
    [123] Meng L, Zheng Y, Hui R (2013) The relationship of sleep duration and insomnia to risk of hypertension incidence: a meta-analysis of prospective cohort studies. Hypertens Res 36: 985-995. doi: 10.1038/hr.2013.70
    [124] Palagini L, Bruno RM, Gemignani A, et al. (2013) Sleep loss and hypertension: a systematic review. Curr Pharm Des 19: 2409-2419. doi: 10.2174/1381612811319130009
    [125] Suka M, Yoshida K, Sugimori H (2003) Persistent insomnia is a predictor of hypertension in Japanese male workers. J Occup Health 45: 344-350. doi: 10.1539/joh.45.344
    [126] Vgontzas AN, Liao D, Bixler EO, et al. (2009) Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep 32: 491-497.
    [127] Fernandez-Mendoza J, Vgontzas AN, Liao D, et al. (2012) Insomnia with objective short sleep duration and incident hypertension: the Penn State Cohort. Hypertension 60: 929-935. doi: 10.1161/HYPERTENSIONAHA.112.193268
    [128] Chung WS, Lin CL, Chen YF, et al. (2013) Sleep disorders and increased risk of subsequent acute coronary syndrome in individuals without sleep apnea: a nationwide population-based cohort study. Sleep 36: 1963-1968.
    [129] Vozoris NT (2013) The relationship between insomnia symptoms and hypertension using United States population-level data. J Hypertens 31: 663-671. doi: 10.1097/HJH.0b013e32835ed5d0
    [130] Phillips B, Buzkova P, Enright P (2009) Insomnia did not predict incident hypertension in older adults in the cardiovascular health study. Sleep 32: 65-72.
    [131] Phillips B, Mannino DM (2007) Do insomnia complaints cause hypertension or cardiovascular disease? J Clin Sleep Med 3: 489-494.
    [132] Ayas NT, White DP, Manson JE, et al. (2003) A prospective study of sleep duration and coronary heart disease in women. Arch Intern Med 163: 205-209. doi: 10.1001/archinte.163.2.205
    [133] Hoevenaar-Blom MP, Spijkerman AM, Kromhout D, et al. (2011) Sleep duration and sleep quality in relation to 12-year cardiovascular disease incidence: the MORGEN study. Sleep 34: 1487-1492.
    [134] Mallon L, Broman JE, Hetta J (2002) Sleep complaints predict coronary artery disease mortality in males: a 12-year follow-up study of a middle-aged Swedish population. J Intern Med 251: 207-216. doi: 10.1046/j.1365-2796.2002.00941.x
    [135] Wang Q, Xi B, Liu M, et al. (2012) Short sleep duration is associated with hypertension risk among adults: a systematic review and meta-analysis. Hypertens Res 35: 1012-1018. doi: 10.1038/hr.2012.91
    [136] Cappuccio FP, Cooper D, D'Elia L, et al. (2011) Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Eur Heart J 32: 1484-1492. doi: 10.1093/eurheartj/ehr007
    [137] Sabanayagam C, Shankar A, Buchwald D, et al. (2011) Insomnia symptoms and cardiovascular disease among older American Indians: the Native Elder Care Study. J Environ Public Health 2011: 964617.
    [138] Heslop P, Smith GD, Metcalfe C, et al. (2002) Sleep duration and mortality: The effect of short or long sleep duration on cardiovascular and all-cause mortality in working men and women. Sleep Med 3: 305-314. doi: 10.1016/S1389-9457(02)00016-3
    [139] Kronholm E, Laatikainen T, Peltonen M, et al. (2011) Self-reported sleep duration, all-cause mortality, cardiovascular mortality and morbidity in Finland. Sleep Med 12: 215-221. doi: 10.1016/j.sleep.2010.07.021
    [140] Ikehara S, Iso H, Date C, et al. (2009) Association of sleep duration with mortality from cardiovascular disease and other causes for Japanese men and women: the JACC study. Sleep 32: 295-301.
    [141] Suzuki E, Yorifuji T, Ueshima K, et al. (2009) Sleep duration, sleep quality and cardiovascular disease mortality among the elderly: a population-based cohort study. Prev Med 49: 135-141. doi: 10.1016/j.ypmed.2009.06.016
    [142] Dew MA, Hoch CC, Buysse DJ, et al. (2003) Healthy older adults' sleep predicts all-cause mortality at 4 to 19 years of follow-up. Psychosom Med 65: 63-73. doi: 10.1097/01.PSY.0000039756.23250.7C
    [143] Kripke DF, Garfinkel L, Wingard DL, et al. (2002) Mortality associated with sleep duration and insomnia. Arch Gen Psychiatry 59: 131-136. doi: 10.1001/archpsyc.59.2.131
    [144] LeBlanc M, Merette C, Savard J, et al. (2009) Incidence and risk factors of insomnia in a population-based sample. Sleep 32: 1027-1037.
    [145] Morin CM, LeBlanc M, Daley M, et al. (2006) Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Med 7: 123-130. doi: 10.1016/j.sleep.2005.08.008
    [146] Ohayon M (1996) Epidemiological study on insomnia in the general population. Sleep 19: S7-15.
    [147] Ohayon MM (2002) Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 6: 97-111. doi: 10.1053/smrv.2002.0186
    [148] Buysse DJ (2014) Sleep health: can we define it? Does it matter? Sleep 37: 9-17.
    [149] Besedovsky L, Lange T, Born J (2012) Sleep and immune function. Pflugers Arch 463: 121-137. doi: 10.1007/s00424-011-1044-0
    [150] Redwine L, Hauger RL, Gillin JC, et al. (2000) Effects of sleep and sleep deprivation on interleukin-6, growth hormone, cortisol, and melatonin levels in humans. J Clin Endocrinol Metab 85: 3597-3603.
    [151] Meier-Ewert HK, Ridker PM, Rifai N, et al. (2004) Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol 43: 678-683. doi: 10.1016/j.jacc.2003.07.050
    [152] Haack M, Sanchez E, Mullington JM (2007) Elevated inflammatory markers in response to prolonged sleep restriction are associated with increased pain experience in healthy volunteers. Sleep 30: 1145-1152.
    [153] Vgontzas AN, Zoumakis E, Bixler EO, et al. (2004) Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. J Clin Endocrinol Metab 89: 2119-2126. doi: 10.1210/jc.2003-031562
    [154] van Leeuwen WM, Lehto M, Karisola P, et al. (2009) Sleep restriction increases the risk of developing cardiovascular diseases by augmenting proinflammatory responses through IL-17 and CRP. PLoS One 4: e4589. doi: 10.1371/journal.pone.0004589
    [155] Abedelmalek S, Chtourou H, Aloui A, et al. (2013) Effect of time of day and partial sleep deprivation on plasma concentrations of IL-6 during a short-term maximal performance. Eur J Appl Physiol 113: 241-248. doi: 10.1007/s00421-012-2432-7
    [156] Schmid SM, Hallschmid M, Jauch-Chara K, et al. (2011) Disturbed glucoregulatory response to food intake after moderate sleep restriction. Sleep 34: 371-377.
    [157] Stamatakis KA, Punjabi NM (2010) Effects of sleep fragmentation on glucose metabolism in normal subjects. Chest 137: 95-101. doi: 10.1378/chest.09-0791
    [158] Faraut B, Boudjeltia KZ, Dyzma M, et al. (2011) Benefits of napping and an extended duration of recovery sleep on alertness and immune cells after acute sleep restriction. Brain Behav Immun 25: 16-24. doi: 10.1016/j.bbi.2010.08.001
    [159] Shearer WT, Reuben JM, Mullington JM, et al. (2001) Soluble TNF-alpha receptor 1 and IL-6 plasma levels in humans subjected to the sleep deprivation model of spaceflight. J Allergy Clin Immunol 107: 165-170. doi: 10.1067/mai.2001.112270
    [160] Irwin M, Rinetti G, Redwine L, et al. (2004) Nocturnal proinflammatory cytokine-associated sleep disturbances in abstinent African American alcoholics. Brain Behav Immun 18: 349-360. doi: 10.1016/j.bbi.2004.02.001
    [161] Irwin M, Mascovich A, Gillin JC, et al. (1994) Partial sleep deprivation reduces natural killer cell activity in humans. Psychosom Med 56: 493-498. doi: 10.1097/00006842-199411000-00004
    [162] Irwin M, McClintick J, Costlow C, et al. (1996) Partial night sleep deprivation reduces natural killer and cellular immune responses in humans. Faseb j 10: 643-653.
    [163] Vgontzas AN, Pejovic S, Zoumakis E, et al. (2007) Daytime napping after a night of sleep loss decreases sleepiness, improves performance, and causes beneficial changes in cortisol and interleukin-6 secretion. Am J Physiol Endocrinol Metab 292: E253-261.
    [164] Faraut B, Nakib S, Drogou C, et al. (2015) Napping reverses the salivary interleukin-6 and urinary norepinephrine changes induced by sleep restriction. J Clin Endocrinol Metab 100: E416-426. doi: 10.1210/jc.2014-2566
    [165] Chaput JP, Despres JP, Bouchard C, et al. (2008) The association between sleep duration and weight gain in adults: a 6-year prospective study from the Quebec Family Study. Sleep 31: 517-523.
    [166] Patel SR, Malhotra A, White DP, et al. (2006) Association between reduced sleep and weight gain in women. Am J Epidemiol 164: 947-954. doi: 10.1093/aje/kwj280
    [167] Cappuccio FP, D'Elia L, Strazzullo P, et al. (2010) Quantity and quality of sleep and incidence of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care 33: 414-420. doi: 10.2337/dc09-1124
    [168] Cooper AJ, Westgate K, Brage S, et al. (2015) Sleep duration and cardiometabolic risk factors among individuals with type 2 diabetes. Sleep Med 16: 119-125. doi: 10.1016/j.sleep.2014.10.006
    [169] Lou P, Qin Y, Zhang P, et al. (2015) Association of sleep quality and quality of life in type 2 diabetes mellitus: A cross-sectional study in China. Diabetes Res Clin Pract 107: 69-76. doi: 10.1016/j.diabres.2014.09.060
    [170] Spiegel K, Tasali E, Penev P, et al. (2004) Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med 141: 846-850. doi: 10.7326/0003-4819-141-11-200412070-00008
    [171] Spiegel K, Leproult R, Van Cauter E (1999) Impact of sleep debt on metabolic and endocrine function. Lancet 354: 1435-1439. doi: 10.1016/S0140-6736(99)01376-8
    [172] Conlon M, Lightfoot N, Kreiger N (2007) Rotating shift work and risk of prostate cancer. Epidemiology 18: 182-183. doi: 10.1097/01.ede.0000249519.33978.31
    [173] Kubo T, Ozasa K, Mikami K, et al. (2006) Prospective cohort study of the risk of prostate cancer among rotating-shift workers: findings from the Japan collaborative cohort study. Am J Epidemiol 164: 549-555. doi: 10.1093/aje/kwj232
    [174] Kubo T, Oyama I, Nakamura T, et al. (2011) Retrospective cohort study of the risk of obesity among shift workers: findings from the Industry-based Shift Workers' Health study, Japan. Occup Environ Med 68: 327-331. doi: 10.1136/oem.2009.054445
    [175] Parent ME, El-Zein M, Rousseau MC, et al. (2012) Night work and the risk of cancer among men. Am J Epidemiol 176: 751-759. doi: 10.1093/aje/kws318
    [176] Schwartzbaum J, Ahlbom A, Feychting M (2007) Cohort study of cancer risk among male and female shift workers. Scand J Work Environ Health 33: 336-343. doi: 10.5271/sjweh.1150
    [177] Haus EL, Smolensky MH (2013) Shift work and cancer risk: potential mechanistic roles of circadian disruption, light at night, and sleep deprivation. Sleep Med Rev 17: 273-284. doi: 10.1016/j.smrv.2012.08.003
    [178] von Ruesten A, Weikert C, Fietze I, et al. (2012) Association of sleep duration with chronic diseases in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study. PLoS One 7: e30972. doi: 10.1371/journal.pone.0030972
    [179] Jiao L, Duan Z, Sangi-Haghpeykar H, et al. (2013) Sleep duration and incidence of colorectal cancer in postmenopausal women. Br J Cancer 108: 213-221. doi: 10.1038/bjc.2012.561
    [180] Zhang X, Giovannucci EL, Wu K, et al. (2013) Associations of self-reported sleep duration and snoring with colorectal cancer risk in men and women. Sleep 36: 681-688.
    [181] Bishop D (2008) An applied research model for the sport sciences. Sports Med 38: 253-263. doi: 10.2165/00007256-200838030-00005
    [182] Drust B, Waterhouse J, Atkinson G, et al. (2005) Circadian rhythms in sports performance--an update. Chronobiol Int 22: 21-44. doi: 10.1081/CBI-200041039
    [183] Fullagar HH, Skorski S, Duffield R, et al. (2015) Sleep and Athletic Performance: The Effects of Sleep Loss on Exercise Performance, and Physiological and Cognitive Responses to Exercise. Sports Med 45(2):161-86.
    [184] Hausswirth C, Louis J, Aubry A, et al. (2014) Evidence of disturbed sleep and increased illness in overreached endurance athletes. Med Sci Sports Exerc 46: 1036-1045. doi: 10.1249/MSS.0000000000000177
    [185] Gleeson M (2007) Immune function in sport and exercise. J Appl Physiol (1985) 103: 693-699. doi: 10.1152/japplphysiol.00008.2007
    [186] Samuels C (2008) Sleep, recovery, and performance: the new frontier in high-performance athletics. Neurol Clin 26: 169-180; ix-x. doi: 10.1016/j.ncl.2007.11.012
    [187] Durmer JS, Dinges DF (2005) Neurocognitive consequences of sleep deprivation. Semin Neurol 25: 117-129. doi: 10.1055/s-2005-867080
    [188] Venter RE (2014) Perceptions of team athletes on the importance of recovery modalities. Eur J Sport Sci 14 Suppl 1: S69-76.
    [189] Erlacher D, Ehrlenspiel F, Adegbesan OA, et al. (2011) Sleep habits in German athletes before important competitions or games. J Sports Sci 29: 859-866. doi: 10.1080/02640414.2011.565782
    [190] Juliff LE, Halson SL, Peiffer JJ (2015) Understanding sleep disturbance in athletes prior to important competitions. J Sci Med Sport 18: 13-18. doi: 10.1016/j.jsams.2014.02.007
    [191] Hanton S, Fletcher D, Coughlan G (2005) Stress in elite sport performers: a comparative study of competitive and organizational stressors. J Sports Sci 23: 1129-1141. doi: 10.1080/02640410500131480
    [192] Chen JC, Brunner RL, Ren H, et al. (2008) Sleep duration and risk of ischemic stroke in postmenopausal women. Stroke 39: 3185-3192. doi: 10.1161/STROKEAHA.108.521773
    [193] Chien KL, Chen PC, Hsu HC, et al. (2010) Habitual sleep duration and insomnia and the risk of cardiovascular events and all-cause death: report from a community-based cohort. Sleep 33: 177-184.
    [194] Gangwisch JE, Malaspina D, Boden-Albala B, et al. (2005) Inadequate sleep as a risk factor for obesity: analyses of the NHANES I. Sleep 28: 1289-1296.
    [195] Cappuccio FP, D'Elia L, Strazzullo P, et al. (2010) Sleep duration and all-cause mortality: a systematic review and meta-analysis of prospective studies. Sleep 33: 585-592.
    [196] Machado RM, Koike MK (2014) Circadian rhythm, sleep pattern, and metabolic consequences: an overview on cardiovascular risk factors. Horm Mol Biol Clin Investig 18: 47-52.
    [197] Petrov ME, Lichstein KL (2015) Differences in sleep between black and white adults: an update and future directions. Sleep Med Jan 23, in press.
  • This article has been cited by:

    1. Zamra Sajid, Morten Andersen, Johnny T. Ottesen, System dynamics of cancer in erythropoiesis with multiple EPO feedbacks , 2020, 36, 0883-7066, 447, 10.1002/sdr.1670
    2. Johnny T. Ottesen, Rasmus K. Pedersen, Marc J. B. Dam, Trine A. Knudsen, Vibe Skov, Lasse Kjær, Morten Andersen, Mathematical Modeling of MPNs Offers Understanding and Decision Support for Personalized Treatment, 2020, 12, 2072-6694, 2119, 10.3390/cancers12082119
    3. Morten Andersen, Hans C. Hasselbalch, Lasse Kjær, Vibe Skov, Johnny T. Ottesen, Global dynamics of healthy and cancer cells competing in the hematopoietic system, 2020, 326, 00255564, 108372, 10.1016/j.mbs.2020.108372
    4. Rasmus Kristoffer Pedersen, Morten Andersen, Vibe Skov, Lasse Kjær, Hans C Hasselbalch, Johnny T Ottesen, Thomas Stiehl, HSC Niche Dynamics in Regeneration, Pre-malignancy, and Cancer: Insights From Mathematical Modeling, 2022, 1066-5099, 10.1093/stmcls/sxac079
    5. Mia Brunetti, Michael C. Mackey, Morgan Craig, Understanding Normal and Pathological Hematopoietic Stem Cell Biology Using Mathematical Modelling, 2021, 7, 2198-7866, 109, 10.1007/s40778-021-00191-9
    6. Mia Brunetti, Isabella A. Iasenza, Adrianne L. Jenner, Noël J.-M. Raynal, Kolja Eppert, Morgan Craig, Mathematical modelling of clonal reduction therapeutic strategies in acute myeloid leukemia, 2024, 140, 01452126, 107485, 10.1016/j.leukres.2024.107485
    7. Thomas Stiehl, 2023, Chapter 73, 978-3-031-28048-1, 327, 10.1007/16618_2023_73
  • Reader Comments
  • © 2015 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(24935) PDF downloads(9467) Cited by(11)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog